


BH
BA



Publication number

0 356 223
A2

①

EUROPEAN PATENT APPLICATION

② Application number: 89306566.5

③ Date of filing: 23.08.89

④ Int. Cl.³: C 07 K 5/02
A 61 K 37/64, C 07 D 237/22,
C 07 D 311/06,
C 07 D 207/333

⑤ Priority: 24.08.88 US 38486 28.03.89 US 328645

⑥ Date of publication of application:
28.02.90 Bulletin 90/08

⑦ Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

⑧ Applicant: MERCK & CO. INC.
126, East Lincoln Avenue P.O. Box 2000
Rahway New Jersey 07065-0800 (US)

⑨ Inventor: Decolme, S. Jane
736 Port Indian Road
Norristown PA 19403 (US)

Hull, Joel R.
736 Bergey Mill Road
Ladysburg PA 19450 (US)

Vacca, Joseph P.
788 Eisenhower Drive
Telford PA 18660 (US)

Sigal, Irving S.
Deceased (US)

Darke, Paul L.
434 West Walnut Street
North Wales PA 19454 (US)

Young, Steven D.
128 Mark Drive
Lanedale PA 19446 (US)

⑩ Representative: Heeketh, Alan, Dr. et al
European Patent Department Merck & Co., Inc. Terlings
Park Eastwick Road
Harlow Essex, CM20 2QR (GB)

⑪ HIV protease inhibitors useful for the treatment of aids.

⑫ Compounds of the form,
A-G-B-S-J

wherein A is an amine protecting group not useful or commonly employed in peptide synthesis, G a dipeptide isostere, B an amino acid or analog thereof, and J a small terminal group are described. These compounds are useful in the inhibition of HIV protease, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

EP 0 356 223 A2

Description

HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS

The present invention is concerned with compounds which inhibit the protease encoded by human immunodeficiency virus (HIV) or pharmaceutically acceptable salts thereof and are of value in the prevention of infection by HIV, treatment of infection by HIV and the treatment of the resulting acquired immune deficiency syndrome (AIDS). It also relates to pharmaceutical compositions containing the compounds and to a method of use of the present compounds and other agents for the treatment of AIDS.

BACKGROUND OF THE INVENTION

A retrovirus designated human immunodeficiency virus (HIV) is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system. This virus was previously known as LAV, HTLV-III, or ARV. A common feature of retrovirus replication is the extensive post-translational processing or precursor polyproteins by a virally encoded protease to generate mature viral proteins required for virus assembly and function. Interruption of this processing appears to prevent the production of normally infectious virus. For example, Crawford, S. et al., J. Virol., 53, 899, 1985, demonstrated that genetic deletion mutations of the protease in murine leukemia virus which prevent processing of precursor structural proteins results in non-infectious viral particles. Unprocessed structural proteins also have been observed in clones of non-infectious HIV strains isolated from human patients. These results suggest that inhibition of the HIV protease represents a viable method for the treatment of AIDS or the prevention of infection by HIV.

Nucleotide sequencing of HIV shows the presence of a *pol* gene in one open reading frame [Ratner, L. et al., Nature, 313, 277(1985)]. Amino acid sequence homology provides evidence that the *pol* sequence encodes reverse transcriptase, an endonuclease and an HIV protease [Toh, H. et al., EMBO J. 4, 1267(1985); Power, M.D. et al., Science, 231, 1567(1986); Pearl, L.H. et al. Nature 329, 351(1987)]. Applicants demonstrate that the compounds of this invention are inhibitors of HIV protease.

BRIEF DESCRIPTION OF THE INVENTION

Compounds of formula I, as herein defined, are disclosed. These compounds are useful in the inhibition of HIV protease, the prevention of infection by HIV, the treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also disclosed

ABBREVIATIONS

<u>Designation</u>	<u>Amino Acid/Residue</u>
Ala	D- or L-alanine
Arg	D- or L-arginine
Cal (Cha)	B-cyclohexylalanine
Cys	D- or L-cysteine
Gly	glycine
His	D- or L-histidine
Ile	L-isoleucine
Leu	D- or L-leucine
Lys	D- or L-lysine
Met	D- or L-methionine

<u>Designation</u>	<u>Amino Acid/Residue</u>
Nle	L-norleucine
Nva	L-norvaline
Orn	D- or L-ornithine
Ph	phenyl
Phe	D- or L-phenylalanine
Pro	D- or L-proline
Sar	sarcosine (N-methylglycine)
Ser	D- or L-serine
Sta	statine, (3S,4S)-4-amino-3-hydroxy-6-methylheptanoic acid
Thr	D- or L-threonine
Trp	D- or L-tryptophan
Tyr	D- or L-tyrosine
Val	L-valine
	<u>Protecting Group</u>
BOC (Boc)	t-butyloxycarbonyl
BOM	benzyloxymethyl
CBZ (Cbz)	benzyloxycarbonyl(carbo-benzoyl)
DNP	2,4-dinitrophenyl
IPOC	isopropoxycarbonyl
OMe	methyl ether (methoxy), except when it immediately follows an amino acid residue abbreviation and it represents methyl ester.

Designation

OEt

TBDMS-Cl

HBT(HOBT)

OMs

DCCI (DCC)

DPPA

(BOC)₂O

DEAD

MCPBA

TEA

TFA

BOP reagent

BOP-Cl

DSO

Designation

EDC

Reagent

ethoxy, except when it immediately follows an amino acid residue abbreviation and it represents ethyl ester

t-butyldimethylsilyl chloride

Activating Group

1-hydroxybenzotriazole hydrate

methane sulfonyloxy

Condensing Agent

dicyclohexylcarbodiimide

diphenylphosphorylazide

di-t-butyl dicarbonate

diethyl azodicarboxylate

3-chloropenoxybenzoic acid

triethylamine

trifluoroacetic acid

Coupling Reagents

benzotriazol-1-yloxytris-(dimethyl-amino)phosphonium hexafluorophosphate

bis(2-oxo-3-oxazolidinyl)phosphinic chloride

N,N'-disuccinimidyl oxalate

Reagent

1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride

DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS

This invention is concerned with the use of Compounds of Formula I, combinations thereof, or pharmaceutically acceptable salts thereof, in the inhibition of HIV protease, the prevention of infection by HIV, the treatment of infection by HIV and in the treatment of the resulting acquired immune deficiency syndrome (AIDS). Compounds of Formula I are defined as follows:

A-G-B-B-J I,

wherein A is

1)

$\text{R}^1-\overset{\text{O}}{\underset{\text{||}}{\text{C}}}-$ wherein R^1 is

a) C_{1-4} alkyl either unsubstituted or substituted with one or more of

i) C_{1-4} alkyl;

ii) hydroxy;

iii) carboxy;

iv) halo wherein halo is F, Cl, Br, or I; except no halo on carbon adjacent to carbonyl;

v) amino;

vi) C_{1-3} alkoxy; carbonyl;

vii) C_{1-3} alkoxy;


viii) $-\text{CONR}^2\text{R}^3$ wherein R^2 and R^3 are the same or different and are hydrogen, C_{1-4} alkyl or C_{1-3} alkoxyalkyl or joined together either directly to form a 5-7 membered heterocycle such as pyrrolidinyl or piperidinyl, or through a heteroatom selected from N, O, and S, to form a 6-membered heterocycle with the nitrogen to which they are attached such as morpholinyl, piperazinyl, or N- C_{1-3} alkylpiperazinyl;

ix) $-\text{NR}^2\text{R}^3$;

x) $-\overset{\text{R}}{\underset{\text{||}}{\text{N}}}-\text{P}-\text{R}^4$ wherein,

R is hydrogen or C_{1-4} alkyl,

P is



and

R^4 is H, C_{1-3} alkyl, C_{1-4} alkoxy, or NR^2R^3 ;

xi) C_{3-7} cycloalkyl or C_{6-10} aryl;

xii) 5 or 6 membered heterocycle, unsubstituted or substituted with $-\text{OH}$, NH , or C_{1-4} alkyl; or

xiii) aryl of 6-10 carbon atoms, either unsubstituted or substituted with one or more of

(a) halo,

(b) hydroxy,

(c) C_{1-3} alkoxy,


(d) C_{1-3} alkyl,

(e) $-\text{NR}_2$, wherein R is defined above,

(f)




(g)



(h) $-\text{SO}_2\text{NR}_2$,

(i) $-\text{CH}_2\text{NR}_2$,

(j)



or


(k) $-\overset{\text{R}}{\underset{\text{||}}{\text{N}}}-\text{SO}_2\text{R}$;

xiv) $-\text{OSiR}^3(\text{R}^2)_2$;

b) aryl of 6-10 carbon atoms, either unsubstituted or substituted with one or more of


i) C_{1-4} alkyl,

- ii) C₁₋₃ alkoxy,
 iii) hydroxy, or
 iv) halo;
 v) -NR₂;
 5 vi) $\begin{array}{c} \text{O} \\ || \\ -\text{C}-\text{OR}, \end{array}$
 vii) $\begin{array}{c} \text{O} \\ || \\ -\text{C}-\text{NR}_2, \end{array}$
 10 viii) -SO₂NR₂,
 ix) -CH₂NR₂,
 x) -NRCOR, or
 xi) -NRSO₂R;
 15 c) 5 or 6 membered heterocycle as defined below;
 2) R¹-SO₂-, except R¹ is not aryl.
 3)




wherein

- 25 R⁵ is H or C₁₋₆ alkyl or joined together with R¹ either directly to form 5-7 membered heterocycle such as pyrrolidinyl or piperidinyl, or through a heteroatom selected from N, O, and S, to form a 6-membered heterocycle with the nitrogen to which they are attached such as morpholinyl, piperazinyl, or N-C₁₋₃ alkyl-piperazinyl;
 4)



- 35 5) $\text{R}^1-\text{S}-\text{C}-$;
 6) (R¹)_q, wherein q is 1 or 2.
 40 G is



- 50 wherein Z is O, S, or NH, and
 R⁹ is independently
 1) hydrogen;
 2)



- 60 3) -OR, wherein R is H, or C₁₋₄ alkyl
 4) -NR₂,
 5) C₁₋₄ alkylene-R¹¹;
 wherein n is 0-5 and R¹⁰ is independently
 65 a) hydrogen.

- b) hydroxy, or
 c) C₁₋₄-alkyl;
 R¹¹ is
 a) hydrogen
 b) aryl, unsubstituted or substituted with one or more of
 i) halo, 5
 ii) hydroxy,
 iii) -NH₂, -NO₂, -NHR, or -NR₂,
 wherein R is
 H, or C₁₋₄ alkyl,
 iv) C₁₋₄ alkyl, 10
 v) C₁₋₃ alkoxy,
 vi) -COOR,
 vii)

$$\begin{array}{c} \text{O} \\ \parallel \\ -\text{C} \text{NR}_2 \end{array}$$
 15
 viii) -CH₂NR₂,
 ix)

$$\begin{array}{c} \text{O} \\ \parallel \\ -\text{CH}_2\text{NH} \text{C} \text{R} \end{array}$$
 20
 x) CN,
 xi) CF₃,
 xii)

$$\begin{array}{c} \text{O} \\ \parallel \\ -\text{NH} \text{C} \text{R} \end{array}$$
 25
 xiii) aryl C₁₋₃ alkoxy,
 xiv) aryl,
 xv) -NRSO₂R,
 xvi) -OP(O)(OR_n)₂ wherein R_n is H or aryl, or
 xvii) 30

$$\begin{array}{c} \text{O} \\ \parallel \\ -\text{O} \text{C} \end{array}$$
 C₁₋₄ alkyl substituted with one or more of amine or quaternary amine;
 c) 5 or 6 membered heterocycle including up to 3 heteroatoms selected from N, O, and S, such as imidazolyl,
 thiazolyl, furyl, oxazolyl, piperidyl, thiadiazolyl, piperazinyl, pyridyl, or pyrazinyl, any of which heterocycle may
 be unsubstituted or substituted with one or more of 35
 i) halo,
 ii) hydroxy,
 iii) -NH₂, -NHR, -NR₂,
 iv) C₁₋₄ alkyl,
 v) C₁₋₃ alkoxy, 40
 vi) -COOR,
 vii)

$$\begin{array}{c} \text{O} \\ \parallel \\ -\text{C} \text{NR}_2 \end{array}$$

 viii) -CH₂NR₂, 45
 ix)

$$\begin{array}{c} \text{O} \\ \parallel \\ -\text{NH} \text{C} \text{R} \end{array}$$

 x) -CN,
 xi) CF₃, 50
 xii) -NHSO₂R,
 xiii) -OP(O)(OR_n)₂ wherein R_n is H or aryl, or
 xiv)

$$\begin{array}{c} \text{O} \\ \parallel \\ -\text{O} \text{C} \end{array}$$
 C₁₋₄ alkyl substituted with one or more of amine or quaternary amine; 55
 d) C₁₋₈ alkyl or C₁₋₈ alkenyl, unsubstituted or substituted with one or more of
 i) hydroxy,
 ii) C₁₋₄ alkyl,
 iii) -NH₂, -NHR, -NR₂,
 iv) 60

$$\begin{array}{c} \text{NR}_2 \\ \parallel \\ -\text{NH} \text{C} \end{array}$$

 v)

$$\begin{array}{c} \text{NR}_2 \\ \parallel \\ -\text{NH} \text{C} \end{array}$$
 NH₂, 65


- vi) $-\text{COOH}$,
 vii) $-\text{C}(=\text{O})\text{OR}$,
 5 viii) $-\text{SR}$, or arylthio
 ix) $-\text{SO}_2\text{NHR}$,
 x) C_{1-4} alkyl sulfonyl amino or aryl sulfonyl amino,
 xi) $-\text{CONHR}$,
 xii) $-\text{NH}-\text{C}(=\text{O})\text{R}$,
 10 xiii) $-\text{OR}$,
 xiv) aryl C_{1-3} alkoxy or,
 xv) aryl;
 15 e) C_{3-7} cycloalkyl unsubstituted or substituted with one or more of
 i) hydroxy,
 ii) C_{1-4} alkyl,
 iii) $-\text{NH}_2$, $-\text{NHR}$, $-\text{NHR}_2$,
 iv) $-\text{NH}-\text{C}(=\text{O})\text{NH}_2$,
 20 v) $-\text{NH}-\text{C}(=\text{O})\text{NH}_2$,
 vi) $-\text{COOH}$,
 vii) $-\text{C}(=\text{O})\text{OR}$,
 viii) $-\text{SR}$,
 25 ix) $-\text{SO}_2\text{NH}_2$,
 x) alkyl sulfonylamino or aryl sulfonylamino,
 xi) $-\text{CONHR}$, or
 xii) $-\text{NH}-\text{C}(=\text{O})\text{R}$;
 30 f) a 5- to 7-membered carbocyclic or 7- to 10-membered bicyclic carbocyclic ring which is either saturated or unsaturated, such as cyclopentane, cyclohexane, indan, norbornane, or naphthene, the carbocyclic ring being unsubstituted or substituted with one or more of
 i) halo
 35 ii) $-\text{OR}$, wherein R is H or C_{1-4} alkyl,
 iii) $-\text{C}(=\text{O})\text{OR}$,
 iv) $-\text{C}(=\text{O})\text{NR}_2$,
 40 v) $-\text{CH}_2\text{NR}_2$,
 vi) $-\text{SO}_2\text{NR}_2$ or $-\text{S}(\text{O})_y$, R wherein y is 0, 1 or 2,
 vii) $-\text{NR}_2$,
 45 viii) $-\text{NH}-\text{C}(=\text{O})\text{R}$,
 ix) C_{1-4} alkyl,
 x) phenyl,
 50 xi) $-\text{CF}_3$, or
 xii) $-\text{N}(\text{SO}_2\text{R})_2$;
 g) benzofuryl; indolyl; azabicyclo C_{7-11} cycloalkyl; or benzopiperidiny;
 55 h) R^{12} is $-\text{OH}$ or $-\text{NHR}^{13}$, wherein R^{13} is $-\text{H}$,
 i) $-\text{CH}_2$, $-\text{C}_{1-4}$ -alkyl or $-\text{COOR}$; and
 j) C_{3-7} cycloalkyl either unsubstituted or substituted with one or more of
 60 k) C_{1-4} alkyl,

- b) hydroxy,
 c) $-NR_2$,
 d) $-COOR$,
 e) $CONHR$,
 f) $-NHSO_2R$,
 g)




- h) aryl,
 i) aryl substituted with C_{1-4} alkyl,
 j) heterocycle, or
 k) heterocycle substituted with C_{1-4} alkyl;
 2) phenyl either unsubstituted or substituted with one or more of

- a) hydroxy,
 b) $-OR$,
 c) $-NHR^{13}$,
 d) $-COOR$,
 e)



- 3) 5 to 7-membered heterocycle such as imidazolyl, thiazolyl, furyl, oxazolyl, piperidyl, piperazinyl, pyridyl, or pyrazinyl, any of which heterocycle may be unsubstituted or substituted with one or more of

- i) halo,
 ii) hydroxy,
 iii) NR_2 , or
 iv) C_{1-4} alkyl;
 Q is




wherein R^9 and R^{13} are defined above; X is O, S, or NH; and

W is

- 1) OH,
 2) NH_2 ,
 3) OR, or
 4) NHR;

B is, independently, absent, or



J is

- 1) YR^{14} wherein:






Y is

O or NH, and

R^{14} is

- a) H;
 b) C_{1-4} alkyl, unsubstituted or substituted with one or more of
 i) $-NR_2$,
 ii) $-OR$,
 iii) $-NHSO_2C_{1-4}$ alkyl,
 iv) $-NHSO_2$ aryl, or $-NHSO_2$ (dialkylaminoaryl),
 v) $-CH_2OR$,
 vi) C_{1-4} alkyl,
 vii)






25
 xiii) $-\text{NR}_3^+ \text{A}^-$ wherein A^- is a counterion.
 xiv) $-\text{NR}^{18}\text{R}^{19}$ wherein R^{18} and R^{19} are the same or different and are C_{1-8} alkyl joined together directly to form a 5-7 membered heterocycle.

xv) aryl.
 30
 xvi) $-\text{CHO}$,
 xvii) $-\text{OP}(\text{O})(\text{OR}_2)_2$ wherein R_2 is H or aryl, or
 xviii)

$-\text{O}-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-\text{C}_{1-4}$ alkyl substituted with one or more of amine or quaternary amine;
 35
 c) $-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_3$ or $-(\text{CH}_2\text{CH}_2\text{O})_n\text{H}$;
 2) $-\text{N}(\text{R}^{14})_2$,
 3) $-\text{NR}^{15}\text{R}^{16}$ wherein R^{15} and R^{16} are defined above, or
 4)



wherein:

Y, R^{14} , and n are defined above, and

R^{17} is

a) hydrogen;

b) aryl unsubstituted or substituted with one or more of

i) halo,

ii) $-\text{OR}$, wherein R is H or C_{1-4} alkyl.

35
 iii)



iv)



60
 v) $-\text{CH}_2\text{NR}_2$.

vi) $-\text{SO}_2\text{NR}_2$.

vii) $-\text{NR}_2$.

viii)

65

$\begin{array}{c} \text{O} \\ \parallel \\ \text{-NH-C-R,} \end{array}$	
ix) C ₁₋₄ alkyl,	
x) phenyl,	
xi) -CF ₃ ,	
xii)	
$\begin{array}{c} \text{R} \\ \\ \text{-SO}_2\text{R,} \end{array}$	5
xiii) -C ₁₋₄ alkyl-NR ₂ ,	
xiv) -OP(O)(OR ₂) ₂ wherein R ₂ is H or aryl, or	
xv)	
$\begin{array}{c} \text{O} \\ \parallel \\ \text{-O-C-C}_{1-4} \text{ alkyl substituted with one or more of amine or quaternary amine,} \end{array}$	10
c) heterocycle, unsubstituted or substituted with one or more of	
i) halo,	
ii) -OR, wherein R is H, C ₁₋₄ alkyl, or C ₁₋₄ alkenyl,	
iii)	15
$\begin{array}{c} \text{O} \\ \parallel \\ \text{-C-OR,} \end{array}$	
iv)	
$\begin{array}{c} \text{O} \\ \parallel \\ \text{-C-NR}_2, \end{array}$	20
v) -CH ₂ NR ₂ ,	
vi) -SO ₂ NR ₂ ,	
vii) -NR ₂ ,	
viii)	
$\begin{array}{c} \text{O} \\ \parallel \\ \text{-NH-C-R,} \end{array}$	25
ix) C ₁₋₄ alkyl,	
x) phenyl,	
xi) -CF ₃ ,	
xii)	30
$\begin{array}{c} \text{R} \\ \\ \text{-SO}_2\text{R,} \end{array}$	
xiii) phenyl C ₁₋₄ alkyl,	
xiv)	
$\begin{array}{c} \text{O} \\ \parallel \\ \text{-O-C-R,} \end{array}$	35
xv) -OP(O)(OR ₂) ₂ wherein R ₂ is H or aryl, or	
xvi)	
$\begin{array}{c} \text{O} \\ \parallel \\ \text{-O-C-C}_{1-4} \text{ alkyl substituted with one or more of amine or quaternary amine;} \end{array}$	40
d) A 5- to 7-membered carbocyclic or 7- to 10-membered bicyclic carbocyclic ring which is either saturated or unsaturated, such as cyclopentane, cyclohexane, indan, norbornane or naphthalene, the carbocyclic ring being unsubstituted or substituted with one or more of	
i) halo,	
ii) -OR, wherein R is H or C ₁₋₄ alkyl,	45
iii)	
$\begin{array}{c} \text{O} \\ \parallel \\ \text{-C-OR,} \end{array}$	
iv)	
$\begin{array}{c} \text{O} \\ \parallel \\ \text{-C-NR}_2, \end{array}$	50
v) -CH ₂ NR ₂ ,	
vi) -SO ₂ NR ₂ ,	
vii) -NR ₂ ,	
viii)	55
$\begin{array}{c} \text{O} \\ \parallel \\ \text{-NH-C-R,} \end{array}$	
ix) C ₁₋₄ alkyl,	
x) phenyl,	
xi) -CF ₃ ,	60
xii)	
$\begin{array}{c} \text{R} \\ \\ \text{-SO}_2\text{R,} \end{array}$	
xiii) -OP(O)(OR ₂) ₂ wherein R ₂ is H or aryl, or	
xiv)	65

$$\begin{array}{c} \text{O} \\ \parallel \\ \text{O}-\text{C}-\text{C}_{1-4} \end{array}$$
 alkyl substituted with one or more of amine or quaternary amine; or pharmaceutically acceptable salts.

In the compounds of the present invention, the A, G, B and J components and the like may have asymmetric centers and occur as racemates, racemic mixtures and as individual diastereomers, with all isomeric forms being included in the present invention.


When any variable (e.g., aryl, heterocycle, R, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, A, n, Y, Z, etc.) occurs more than one time in any constituent or in formula I, its definition on each occurrence is independent of its definition at every other occurrence. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

As used herein except where noted, "alkyl" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms (Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl); "alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge; "carboxy" is -COOH; and "cycloalkyl" is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl (Cyh) and cycloheptyl; "alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, butenyl, pentenyl, and the like. "Halo", as used herein, means fluoro, chloro, bromo and iodo; and "counterion" is used to represent a small, single negatively-charged species, such as chloride, bromide, hydroxide, acetate, trifluoroacetate, perchlorate, nitrate, benzoate, maleate, tartrate, hemitartrate, benzene sulfonate, and the like.


As used herein, with exceptions as noted, "aryl" is intended to mean phenyl (Ph) or naphthyl. "Carbocyclic" is intended to mean any stable 5- to 7-membered carbon ring or 7- to 10-membered bicyclic carbon ring, any of which may be saturated or partially unsaturated.

The term heterocycle, as used herein except where noted, represents a stable 5- to 7-membered mono- or bicyclic or stable 7- to 10-membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen, carbon or sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic elements include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolidinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, indanyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, quinolidinyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl.


One embodiment of the compounds of the present invention encompasses those compounds of Formula I in which B is independently present twice and Z is 0. In this embodiment, it is preferred that J is NH₂ and Q is




A second embodiment of the compounds of the present invention consists of those compounds of Formula I in which B is present once and Z is 0. In this embodiment, it is preferred that Q is




A third embodiment of the compounds of the present invention encompasses those compounds of Formula I in which B is absent. In this embodiment, it is preferred that Q is



A fourth embodiment of the compounds of the present invention encompasses those compounds of Formula I in which G is




A fifth embodiment of the compounds of the present invention encompasses those compounds of formula I in which G is




and B is absent or present or,ca.

A sixth embodiment of the compounds of the present invention encompasses those compounds of Formula I in which G is




B is absent or present once; and




A seventh embodiment of the compounds of the present invention encompasses those compounds of Formula I in which A is

$\text{R}^1 - \overset{\text{O}}{\underset{\text{O}}{\text{C}}} -$ or $\text{R} - \text{SO}_2 -$ with the proviso that R^1 is not aryl when attached to S; G is




B is absent or present once; and

J is




Preferred compounds of the present invention are compounds A, B, C, D, or E, as follows:

A:




N'-(1,1-dimethylethylaminocarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-leucyl-phenylalanylamide;

B:




N'-(2,2-dimethylpropanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-leucyl-phenylalanylamide;

C:




N'-(2-thienoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-leucyl-phenylalanylamide;

D:



N'-(3,3-dimethylbutanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-leucyl-phenylalanyl amide;


E:



N'-(3-phenylpropanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-leucyl-phenylalanyl amide.


Other preferred compounds of the present invention include compounds F, G, H, and J, as follows:

F:




N-benzyl-N'-(succinoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl isoleucyl amide;

G:




N-(2(R)-hydroxy-1(S)-indanyl)-N'-(succinoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanamide;

H:



15 N-(2(R)-hydroxy-1(S)-indanyl)-N'-(methanesulfonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanamide;

J:



30 N-(2(R)-hydroxy-1(S)-indanyl)-N'-(5-oxo-2(S)-tetrahydrofuran-2-yl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanamide, or pharmaceutically acceptable salts thereof.

Other preferred compounds include the following:


35 N'-(2,2-dimethylpropanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanoyl -Leu-Phe-amide,
 N'-(1,1-dimethylethylaminocarbonyl)-5(S)-amino-4(S)-hydroxy-2(R)-phenylmethyl-hexanoyl-Leucyl-Phenylalanyl-amide,
 40 N'-(3-phenylpropanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanoyl-Leucyl-Phenylalaninyl-amide,
 N'-succinoyl-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-N-(phenylmethyl)-Ile-amide,
 N-(2(R)-hydroxy-1(S)-indanyl)-N'-(4-[1-butyl-1-dimethylsilyloxybutano]-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanamide,
 45 N-(2(R)-hydroxy-1(S)-indanyl)-N'-(methanesulfonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanamide,
 N-(2(R)-hydroxy-1(S)-indanyl)-N'-(4-hydroxybutanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethyl-hexanamide,
 N-(2(R)-hydroxy-1(S)-indanyl)-N'-(2-(2-(2-methoxyethoxy)ethoxy)ethoxycarbonyl)-5(S)-amino-2(R)-benzyl-4(S)-hydroxy-6-phenylhexanamide,
 N'-(methanesulfonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-N-[2,3-dihydroxypropyl]-Val amide,
 or pharmaceutically acceptable salts thereof.

50 The pharmaceutically-acceptable salt or salts of the compounds of Formula I (in the form of water- or oil-soluble or dispersible products) include the conventional non-toxic salts or the quaternary ammonium salts of these compounds, which are formed, e.g., from inorganic or organic acids or bases. Examples of such acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pantoate, pectinate, persulfate, 3-phenyl-propionate, picrate, phthalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts,
 60 salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diaryl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and their
 65 HIV protease inhibitors of Formula I may be prepared in accordance with well-known procedures for


preparing peptide analogs from their constituent amino acids or analogs thereof.

In general, once the G substituent is made, the rest of the synthesis follows the principle and practice of amide bond formation by the coupling methods of either solution-phase or solid-phase peptide synthesis. The addition and removal of one or more protecting groups is also typical practice.

Structures and abbreviations for the G components of the inhibitors of the present invention include:



a hydroxyethylene dipeptide isostere prepared, for example, by an intermediate lactone according to Evans, B.E. et al J. Org. Chem. 50, 4615(1985) or Kempf, D.J. J. Org. Chem. 51, 3921(1986). Synthetic routes to similar peptide bond isosteres, such as



are readily available. The intermediate BOC-Cal[CH(OH)CH₂]Val-OH lactone is obtained from intermediates prepared using methods described by P. Buhmayer et al. in Published European Patent Application 184,550-A2. Other synthetic routes to peptide bond isosteres of like character are described in the following:


a. Szelke et al. in Peptides, Structure and Function. Proceedings of the Eighth American Peptide Symp (ed. V.J. Hruby and D.H. Rich) pp. 579-82, Pierce Chemical Co., Rockford, IL;

b. D.T. Pals et al in European Patent Appln. 173,481-A2;


c. A.H. Fray et al, J. Org. Chem., 51, 4828-4833 (1986); and

d. M. Szelke et al, PCT Int. Appl. WO 84 03,044;

Structures and abbreviations for other G components of the inhibitors of the present invention include:




with BOC-ACHPA-OEt being prepared by the method described by Boger et al., J. Med. Chem., 28, 1779-1790 (1985);




Statine (Sta)

with BOC-Sta-OEt being prepared in accordance with the procedure described by Rich *et al.*, J. Org. Chem. 43, 3624 (1978);




AHPPA

with BOC-AHPPA-OEt being prepared as described by Rich *et al.*, J. Org. Chem., 23, 27-33 (1980);




AmACHPA




AmSta

with BOC-AmSta(CBZ)-OH being prepared as shown in the following Scheme, and BOC-AmACHPA(CBZ)-OH being prepared as illustrated in the Scheme by substituting BOC-ACHPA-OEt for BOC-Sta-OEt;

Synthesis of protected 3-amino-3-deoxy-(3S, 4S)-statine:



r.t.
pyridine
1-3 hr.




Evap., 35°C
Pump 2-4 days

Aqueous workup
EtOAc/10% citric acid



(Pre-shaken
before
dissolving
up crude
product)

Oiled out from
EtOAc/Hexane



greater than 95% yield


greater than 95% purity (TLC, NMR)






+ 20% elimination

Aqueous
workup


100% elimination

CHCl₃/EtOHPtO₂/H₂
40 lbs., 4 hr.



(predominantly R at position 3
as shown).

Base hydrolysis gives the free acid for incorporation into the synthesis of the compounds of Formula I; or alternatively, this material may be prepared as described by Jones et al. in *Peptides, Structure and Function. Proceedings of the Ninth American Peptide Symposium* (eds. C. M. Deber, V. J. Hruby and K. D. Kopple) pp. 756-62, 1985, Pierce Chemical Co., Rockford, IL.; Arrowmith et al. *J. Chem. Soc. Chem. Commun.* 755-7 (1986); and Raddatz et al. *Published Eur. Pat. Appl.* 161,588; with efficient methods for preparing the 2-substituted statine component G (such as



in a suitably protected form being described in Pub. Eur. Pat. Appln. 157,409 (with other pertinent references including D. Veber et al. *Biochem. Soc. Trans.*, 12, 956-959 (1984) and H. Stein et al. *Fed. Proc.* 45, 869, Abstract No 4151 (1986).


Amide couplings used to form the compounds of this invention are typically performed by the carbodiimide method with reagents such as dicyclohexylcarbodiimide, or N-ethyl, N'-(3-dimethylaminopropyl) carbodiimide. Other methods of forming the amide or peptide bond include, but are not limited to synthetic routes via an acid chloride, azide, mixed anhydride or activated ester. Typically, solution phase amide couplings with or without peptide fragments are performed, but solid-phase synthesis by classical Merrifield techniques may be employed instead.

The selection of protecting groups is, in part, dictated by particular coupling conditions, and in part by the amino acid and peptide components involved in the reaction. The amino-protecting groups ordinarily employed include those which are well-known in the art, for example, urethane protecting substituents such as benzyloxycarbonyl (carbobenzoxy), p-methoxycarbobenzyloxy, p-nitrocarbobenzyloxy, t-butyloxycarbonyl, and the like. It is preferred to utilize t-butyloxycarbonyl (BOC) for protecting the α -amino group, in part because the BOC protecting group is readily removed by relatively mild acids such as trifluoroacetic acid (TFA), or hydrogen chloride in ethyl acetate. By these procedures the A group may be added to deprotected G-B-B-J compounds of Formula I.

The OH group of Thr and Ser may be protected by the Bzl (benzyl) group and the ϵ -amino group of Lys may be protected by the IPOC group or the 2-chlorobenzyloxycarbonyl (2-Cl-CBZ) group. Treatment with HF or catalytic hydrogenation are typically employed for removal of IPOC or 2-Cl-CBZ.


One scheme for preparing compounds of formula I is presented below. Example 1 specifically illustrates the application of the following scheme (I) to specific compounds.

SCHEME I




















Illustrations of the product of Scheme I include the following compounds of Table I.


















TABLE I















 $\text{---R}^9_a\text{---}$ PhCH₂-PhCH₂-PhCH₂-PhCH₂-PhCH₂- $\text{---R}^9_b\text{---}$











-H

-(CH₂)₃CH₃









B groups are added onto the carboxyl terminal end by, for example, amide coupling in Scheme II. See Example I for specific illustration.

SCHEME II

5

10

15

20

25

30

35

40


45

50

55
















60







65




Products of Scheme II include compounds with substituents listed in Table I.


TABLE II



R²_aR²_bR-R-1PhCH₂--LeuPhe(NH₂)CH₃(CH₂)₃--CH₂Ph-LeuPhe(NH₂)PhCH₂--CH₂PhPhCH₂-CH₂PhPhCH₂--LeuPhe(NH₂)PhCH₂--CH₂PhPhCH₂--CH₂PhPhCH₂--CH₂Ph


-LeuPhe

PhCH₂--CH₂Ph



Removal of the Boc protecting group is followed by preparation of the acylated amines according to Scheme III, which is specifically illustrated by Example 1.

SCHEME III




Product compounds of scheme III include those of Table III

TABLE III

5







10

15






20

A





25





30

35



40

45




50

55

Other end groups of the amino terminal side are added by reaction of the amine with the desired acid chloride, as an electrophile, in the reaction in Scheme IV:


60

65





SCHEME IV

wherein A is defined in formula I. See also Example 2. Product compounds of Scheme IV include those of Table IV.



TABLE IV



A	R^9_a	R^9_b	B-D-J
CH_3SO_2^-	PhCH_2^-	$-\text{CH}_2\text{Ph}$	$-\text{Leu Phe NH}_2$
$(\text{CH}_3)_3\text{CNHSO}_2^-$	PhCH_2^-	$-\text{CH}_2\text{CH}=\text{CHPh}$	
		$-\text{CH}_2\text{Ph}$	$-\text{Ile}[\text{NH}_2]$
			$-\text{NHCH}_2\text{Ph}$




Additional J groups are added by Schemes Va and Vb:



Similarly with other J groups under the definition of Formula I. See also Example 4. Product compounds include those of the following Tables.

TABLE Va
















$\text{---R}_a^9\text{---}$	$\text{---R}_b^9\text{---}$	NH-R ¹⁴ and other J groups
PhCH ₂ -	-CH ₂ Ph	-NH-(CH ₂) ₂ CH(CH ₃) ₂
PhCH ₂ -	-CH ₂ Ph	-NH-CH ₂ - 
PhCH ₂ -	-CH ₂ Ph	-NH-CH ₂ - 
PhCH ₂ -	-CH ₂ Ph	-NH-CH()- 
PhCH ₂ -	-CH ₂ Ph	-NH-CH ₂ - 

TABLE Vb





a benzopiperdinyll J group.



The compounds of the present invention are useful in the inhibition of HIV protease, the prevention or treatment of infection by the human immunodeficiency virus (HIV), and the treatment of consequent pathological conditions such as AIDS. Treating AIDS, preventing infection by HIV or treating infection by HIV is defined as including, but not limited to, treating a wide range of states of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIV. For example, the compounds of this invention are useful in preventing infection by HIV after suspected past exposure to HIV by e.g., blood transfusion, accidental needle stick, or exposure to patient blood during surgery.

In the present invention, compounds with asymmetric centers may occur as racemates, racemic mixtures and as individual diastereomers, with all isomeric forms of the compounds being included in the present invention.

For these purposes, the compounds of the present invention may be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation spray, or rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.

Thus, in accordance with the present invention there is further provided a method of treating and a pharmaceutical composition for treating HIV infection and AIDS. The treatment involves administering to a patient in need of such treatment a pharmaceutical composition comprising a pharmaceutical carrier and a therapeutically-effective amount of a compound of the present invention, or a pharmaceutically-acceptable salt thereof.

These pharmaceutical compositions may be in the form of orally-administrable suspensions or tablets; nasal sprays; sterile injectable preparations, for example, as sterile injectable aqueous or oleaginous suspensions or suppositories.

When administered orally as a suspension, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners/flavoring agents known in the art. As immediate release tablets, these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.

When administered by nasal aerosol or inhalation, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability fluoroocarbons, and/or other solubilizing or dispersing agents known in the art.

The injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally-acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.

When rectally administered in the form of suppositories, these compositions may be prepared by mixing the drug with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquify and/or dissolve in the rectal cavity to release the drug.

Dosage levels of the order of 0.02 to 5.0 or 10.0 grams-per-day are useful in the treatment or prevention of the above-indicated conditions, with oral doses two-to-five times higher. For example, infection by HIV is effectively treated by the administration of from 10 to 50 milligrams of the compound per kilogram of body weight from one to three times per day. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination the severity of the particular condition, and the host undergoing therapy.

The present invention is also directed to combinations of the HIV protease-inhibitory compounds with one or more agents useful in the treatment of AIDS.

For example, the compounds of this invention can be given in combination with the antivirals, immunomodulators, antibiotics or vaccines or other derivative forms thereof as listed in the Table VI [source: Marketletter, Nov. 30, 1987, pp. 26-27; Genetic Engineering News, Jan. 1988, Vol. 8, 23]:

TABLE VI¹

A. Antivirals

<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
AL-721	Ethigen	ARC, PGL
BETASERON (interferon beta)	Triton Biosciences	AIDS, ARC, KS
CARRISYN (polymannoacetate)	Carrington Labs	ARC
CYTOVENE (ganciclovir)	Syntex	CMV
DDC (dideoxycytidine)	Hoffmann-La Roche	AIDS, ARC
FOSCARNET (trisodium phosphonoformate)	Astra AB	HIV inf, CMV retinitis

¹Abbreviations: AIDS (Acquired Immune Deficiency Syndrome); ARC (AIDS related complex); CMV (Cytomegalovirus, which causes an opportunistic infection resulting in blindness or death in AIDS patients); HIV (Human Immunodeficiency Virus, previously known as LAV, HTLV-III or ARV); KS (Kaposi's sarcoma); PCP (Pneumocystis carinii pneumonia, an opportunistic infection); PGL (persistent generalized lymphadenopathy).

<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
HPA-23	Rhone-Poulenc Sante	HIV infection
ORNIDYL (eflornithine)	Merrell Dow	PCP
PEPTIDE T (octapeptide sequence)	Peninsula Labs	AIDS
RETICULOSE (nucleophospho- protein)	Advanced Viral Research	AIDS. ARC
RETROVIR (zidovudine; AZT)	Burroughs Wellcome	AIDS, advanced ARC pediatric AIDS. KS, asympt HIV. less severe HIV. neurological in- volvement.
RIFABUTIN (ansamycin LM 427)	Adria Labs	ARC
(trimetrexate)	Warner-Lambert	PCP
UA001	Ueno Fine Chem Industry	AIDS. ARC

<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
VIRAZOLE (ribavirin)	Viratek/ICN	AIDS, ARC, KS
WELLFERON (alfa interferon)	Burroughs Wellcome	KS, HIV, in comb with RETROVIR
ZOVIRAX (acyclovir)	Burroughs Wellcome	AIDS, ARC, KS comb with RETROVIR

B. Immunomodulators

ABPP AIDS, KS (bropiramine)	Upjohn	Advanced
AMPLIGEN (mismatched RNA)	DuPont HEM Research	ARC, PGL
(Anti-human alpha interferon antibody)	Advanced Biotherapy Concepts	AIDS, ARC, KS
Colony Stimulating HIV, Factor (GM-CSF)	Sandoz Genetics Institute	AIDS, ARC, KS
CL246,738 (CL246,738)	American Cynamid	AIDS

<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
IMREG-1 PGL.	Imreg	AIDS, ARC, KS
IMREG-2 PGL.	Imreg	AIDS, ARC, KS
IMUTHIOL (diethyl dithio carbamate)	Merieux Institute	AIDS, ARC
IL-2 (interleukin-2)	Cetus	AIDS, KS
IL-2 (interleukin-2)	Hoffmann-La Roche Immunex	AIDS, KS
INTRON-A (interferon alfa)	Schering-Plough	KS
ISOPRINOSINE (inosine pranobex)	Newport Pharmaceuticals	ARC, PGL, HIV seropositive patients
(methionine enkephalin)	TNI Pharmaceuticals	AIDS, ARC
MTP-PE (muramyl-tripep- tide)	Ciba-Geigy	KS

<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
THYMOPENTIN (TP-5) (thymic compound)	Ortho Pharmaceuticals	HIV infection
ROFERON (interferon alfa)	Hoffmann-La Roche	KS
(recombinant erythropoietin)	Ortho Pharmaceuticals	severe anemia assoc with AIDS & RETROVIR therapy
TREXAN (naltrexone)	DuPont	AIDS, ARC
TNF (tumor necrosis factor)	Genentech	ARC, in combination interferon gamma

C. Antibiotics

PENTAM 300 (pentamidine isethionate)	LyphoMed	PCP
--	----------	-----

D. Vaccines

Any one of a variety of AIDS or HIV vaccines presently under study and development can be used in combination with the compounds of this invention or salt or derivative forms thereof, in the treatment or prevention of AIDS and diseases of similar character caused by HIV.

It will be understood that the scope of combinations of the compounds of this invention with AIDS antivirals, immunomodulators, antibiotics or vaccines is not limited to the list in the above Table, but includes in principle any combination with any pharmaceutical composition useful for the treatment of AIDS.

SYNTHESIS

The preparation and synthesis follows, in general, U.S. Patent 4,661,473; Evans, B.E. et al, J. Org. Chem. 50, 4615, (1985); Evans, B.E. et al., "A Stereocontrolled Synthesis of Hydroxyethylene Dipeptide Isosteres," Proc Am. Pept. Symp., 9, 743-6(199), and Luly, J.R. et al., J. Org. Chem 52, 1487 (1987), all herein incorporated by reference.

EXAMPLE 1

Preparation ofN'-(2-thienocarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanoyl-Leucyl-phenylalanyl amide, Compound C5 Step A: Preparation of3(S)-[(1,1-Dimethylethoxycarbonyl)amino]-2(RS)-hydroxy-4-phenyl-1-trimethylsilylbutane

To a stirred suspension of magnesium turnings (9.79 g, 403 mmol) in dry diethyl ether (200 ml) under nitrogen was added chloromethyltrimethylsilane (50 ml, 358 mmol). The reaction was initiated by gentle warming and then was cooled in an ice bath to maintain gentle reflux. After the exotherm was complete the reaction was stirred at room temperature for 1 hour then cooled to 78°C in a dry ice/acetone bath. To the solution of the Grignard was added dropwise with stirring a solution of N-2(S)-[(1,1-dimethylethoxycarbonyl)amino]-3-phenyl propionaldehyde (19.3 g, 77.4 mmol) in dry diethyl ether (250 ml) dropwise such that the temperature of the reaction remained below -55°C. The resultant gray suspension was allowed to warm to room temperature where it was stirred for 30 minutes then was quenched by pouring into a mixture of ice (500 g) and 10% citric acid (500 ml). The organic phase was collected and the aqueous phase was extracted with diethyl ether (3X300 ml). The combined organics were washed with 10% citric acid (1X300 ml) and brine (1X200 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated to give crude 3(S)-[(1,1-dimethylethoxycarbonyl)amino]-2(RS)-hydroxy-4-phenyl-1-trimethylsilyl butane (26.6 g, quantitative crude yield) as a yellow oil, an analytical sample was obtained by low pressure chromatography (silica gel, 230-400 mesh, diethyl ether:hexanes, 30%:70%) followed by recrystallization from heptane, mp = 91-95°C.

elemental analysis, calcd. for $C_{18}H_{31}NO_3$ Si (337.53):

	C, 64.05;	H, 9.26;	N, 4.15;	
25 Found:	C, 64.15;	H, 9.13;	N, 4.22;	$[\alpha]_D^{20} = -40.0^\circ$

Step B: Preparation of 3(S)-Amino-4-phenyl-1-butene

To a stirred solution of the product of Step A (22.8 g, 67.5 mmol) in dry methylene chloride (400 ml) cooled in an ice bath and under nitrogen was added in a fine stream boron trifluoride etherate (43 ml, 345 mmol). The solution was allowed to warm to room temperature where it was stirred for 4 days. Reaction was cooled in an ice bath and quenched by the dropwise addition to 10% sodium hydroxide (400 ml). The organic phase was collected and the aqueous phase was extracted with methylene chloride (2X250 ml). The combined organics were washed with brine (1X200 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated to give crude 3(S)-amino-4-phenyl-1-butene (14.2 g) as a yellow oil.

Step C: Preparation of N-3(S)-[(1,1-Dimethylethoxycarbonyl)amino]-4-phenyl-1-butene

A solution of the product of Step B (14.2 g) and di-tert-butyl dicarbonate (31.0g, 142 mmol) in dry methylene chloride (200 ml) was stirred at room temperature for 18 hours, washed with 10% citric acid (3X100 ml), water (1X100 ml), sat'd. sodium bicarbonate (3X125 ml), and brine (1X250 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated to yield crude N-3(S)-[(1,1-dimethylethoxycarbonyl)amino]-4-phenylbutene (34.6 g) as a yellow oil. Crude product was purified by low pressure chromatography (silica gel, 230-400 mesh, 10x20 cm column; diethyl ether:hexanes, 20%:80%) to yield N-3(S)-[(1,1-dimethylethoxycarbonyl)amino]-4-phenyl-1-butene (16.3 g, 97.6% yield) as a white solid. An analytical sample was obtained by recrystallization from heptane, mp = 67.5-68.5°C.

elemental analysis, calcd. for $C_{15}H_{21}NO_2$ (247.34):

	C, 72.84;	H, 8.56;	N, 5.66;
50 Found:	C, 72.76;	H, 8.76;	N, 5.64.

Step D: Preparation of 1(R)-[1'(S)-[(1,1-Dimethylethoxycarbonyl)amino-2-phenylethyl]oxirane

To a solution of the product of Step C (9.4 g, 38 mmol) in dry methylene chloride (100 ml) cooled in an ice bath and under nitrogen was added 3-chloroperoxybenzoic acid (technical grade, 80-85%; 41 g, ~200 mmol). The mixture was stirred at 0°C for 18 hours and at 25°C for 23 hours, then diluted with diethyl ether (300 ml), and poured in ice cold aq. 10% sodium sulfite (1 L). The organic layer was collected and the aqueous layer was extracted with diethyl ether (2X100 ml). The combined organics were washed with 10% sodium sulfate (3 x 100 ml), sat'd. sodium bicarbonate (3X100 ml), and brine (1x100 ml), dried over anhyd. sodium sulfate, filtered and concentrated to give a white solid. Crude product was purified by low pressure chromatography (silica gel 230-400 mesh, 8 X 15 cm column; ethyl acetate:hexanes, 25%:75%) to yield 1(R)-[1'(S)-[(1,1-dimethylethoxycarbonyl)amino-2-phenylethyl]oxirane (7.0 g, 70% yield) as a clear oil which crystallized upon standing. An analytical sample was obtained by recrystallization from heptane mp = 51.5-52°C.

elemental analysis, calcd for $C_{15}H_{21}NO_3$ (263.34)

	C, 68.42,	H, 8.04,	N, 5.32	
Found:	C, 68.22,	H, 8.26,	N, 5.29,	$[\alpha]_D^{20} = -1.34$

Step E: Preparation of (5S,1'S)-3-carboethoxy-5-((1,1-dimethylethoxycarbonyl)amino)-2-phenylethyl)-dihydrofuran-2-(3H)-one

The product from Step D, 9.93 g, was dissolved in 100 mL of absolute ethanol and added to a solution of 2.6 g of sodium and 20.1 mL of diethyl malonate in 170 mL of absolute ethanol. After stirring overnight, the reaction was acidified to pH ~ 4 with 10% citric acid and extracted with 2X 500 mL of ether. The combined organic extracts were washed 1X 500 mL H_2O , 1X 500 mL sat'd $NaHCO_3$, 1X 500 mL sat'd brine and dried over $MgSO_4$. The solvents were removed and the crude product purified by low pressure chromatography on silica gel eluting with 50% ether/hexanes (or EtOAc/hexane). The yield of semi-solid product was 10.6 g. The later fractions contained 2.5 g of the undesired 5R isomer as a white solid.

Step F: Preparation of (5S,1'S)-3-carboethoxy-3-phenylmethyl-5-((1,1-dimethylethoxycarbonyl)amino)-2-phenylethyl)-dihydrofuran-2-(3H)-one

The product of Step E, 10.6 g, was dissolved in 100 mL of abs. ethanol containing 3.7 mL of benzyl bromide and added to a solution of 0.71 g of sodium in 100 mL of absolute ethanol. The solution was heated to 50°C for 1.5 hours, then cooled in an ice bath and acidified with 500 mL of 10% citric acid. The mixture was extracted 3X 500 mL of ether and the combined ether extracts washed with 400 mL of H_2O , 400 mL of brine, dried ($MgSO_4$) and the solvent removed under reduced pressure to give 13.6 g of a clear colorless oil which was essentially homogeneous by TLC (25% ethyl acetate/hexanes).

Step G: Preparation of (3R, 5S,1'S)-3-Benzyl-5-((1,1-dimethylethoxycarbonyl)amino)-2-phenylethyl)-dihydrofuran-2-(3H)-one

The product of Step F, 13.6 g, was dissolved in 250 mL of 1,2-dimethoxy ethane, and to it was added 117 mL of 1M lithium hydroxide at room temperature. After stirring for 12 hours, the solvents were removed under reduced pressure, the residue suspended in 200 mL of 10% citric acid and extracted 3X 500 mL of diethyl ether. The combined ether extract were washed with 500 mL of brine, dried ($MgSO_4$) and concentrated to dryness. The residue was dissolved in 250 mL of toluene, heated to reflux for 12 hours, then concentrated to dryness under reduced pressure. Purification by medium pressure chromatography over silica gel, eluting with 15% ethyl acetate/hexanes gave 3.2 g of the 3R-lactone as a clear foam. Further elution with the same solvents gave 6.15 g of the 3S-lactone as a white solid.

Step H: Preparation ofN'-((1,1-dimethylethoxycarbonyl)-5(S)-amino-4(S)-((1',1'-dimethylethyl-1,1-dimethylsilyloxy)-6-phenyl-2(R)-(phenylmethyl)-hexanoic acid

(3R, 5S, 1'S)-3-Benzyl-5-((1,1-dimethylethoxycarbonyl)amino)-2-phenylethyl)-dihydrofuran-2-(3H)-one, 0.5g, was dissolved in 30 mL of a 2:1 mixture of ethylene glycol dimethyl ether/water, and to it was added 5 mL of 1M lithium hydroxide at room temperature. After stirring for 1 hour, the solvent was removed in vacuo and the residue partitioned between 20 mL chloroform and 20 mL 10% citric acid. The layers were separated and the aqueous phase extracted with 3 X 20 mL chloroform. The combined organic layers were dried (Na_2SO_4) and the solvent removed to yield 0.46 g of the crude hydroxy acid. This residue was dissolved in 5 mL of dry DMF and 0.845 g tert-butyl dimethylsilyl chloride and 0.725 g of imidazole were added. After stirring for 18 hours, the reaction was poured into 50 mL of water and extracted with 3 X 20 mL of ethyl acetate. The combined organic extracts were washed with 3 X 20 mL of 10% citric acid, 1 X 20 mL of water, 3 X 10 mL of saturated aqueous solution of Na_2CO_3 , and 20 mL of brine. After drying (Na_2SO_4), the solvent was removed and the resulting residue dissolved in a mixture of 5 mL of THF, 5 mL of glacial acetic acid, and 2 mL of water. The mixture was stirred for 4 hours, then poured into 50 mL of water and extracted with 3 X 20 mL of ether. The combined ether extracts were washed with 2 X 20 mL of water, brine, dried (Na_2SO_4), and the solvent removed. Purification by medium pressure chromatography over silica gel, eluting with MeOH/ $CHCl_3$ gave 0.53 g of the product as a white solid.

Step I: Preparation ofN'-((1,1-dimethylethoxycarbonyl)-5(S)-amino-4(S)-((1',1'-dimethylethyl-1,1-dimethylsilyloxy)-5-phenyl-2(R)-(phenylmethyl)-hexanoyl)-leucyl-phenylalanyl amide.

The product from Step H, 0.183 g, was dissolved in 10 mL of dry DMF, and to it was added 0.124 g of leucyl-phenylalanyl amide hydrochloride hemihydrate, 0.051 g of 1-hydroxybenzotriazole hydrate and 0.069 g of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride. Triethylamine was added to the stirring solution until the pH was 8.5. After stirring for 2 hours, the reaction was poured into 80 mL of water and extracted with 5 X 10 mL of ethyl acetate. The combined organic extracts were washed with 3 X 20 mL of 10% citric acid, 1 X 20 mL of water, 3 X 20 mL of a saturated aqueous solution of Na_2CO_3 , 30 mL of brine, dried

(Na_2SO_4), and the solvent removed to give 0.2 g of the product after purification by preparative thin layer chromatography (50% methanol/chloroform).

Step J: Preparation of

$\text{N}'\text{-(1,1-dimethylethoxycarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-leucyl-phenylalanyl amide}$

The product from Step I, 0.2 g, was placed in a flask and to it was added 2 mL of a 1M solution of tetrabutylammonium fluoride in THF. After stirring for 2 hours, the solvent was removed in vacuo, and the residue was taken up in 50 mL of 10% methanol/chloroform and passed through a pad of silica gel. The solvent was removed in vacuo, and the remaining solid triturated with ethyl acetate. The solid was filtered through a silica pad and washed with ethyl acetate. The silica gel pad was then washed with chloroform (200 mL). The chloroform solution of the product was evaporated to yield 0.074 g of pure product. The ethyl acetate solution was concentrated, and the residue was chromatographed over silica gel, eluting with methanol/chloroform to give an additional 0.054 g of product. The combined yield of the product was 0.128 g; mp 218-210°C.

Step K: The Preparation of

$5(S)\text{-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanoyl-Leucyl-Phenylalanyl Amide}$

To a solution of 350 mgs. (0.49 mmol) of $\text{N}'\text{-(1,1-dimethylethoxy)carbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanoyl-Leucyl-Phenylalanyl Amide}$ dissolved in 15 mL of methylene chloride at 0°C was added 5 mL of trifluoroacetic acid. After 30 minutes, a thin layer chromatogram (TLC) showed that the reaction was complete. The reaction solution was concentrated, the residue dissolved in 25 mL of methylene chloride and transferred to a separatory funnel. The organic layer was washed with 2x50 mL of sat'd. NaHCO_3 solution and the organic layer was dried (Na_2SO_4), filtered and concentrated to give the crude product which was pure enough to be used in the next reaction.

Step L: The preparation of

$\text{N}'\text{-(2-thienocarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanoyl-Leucyl-Phenylalanyl Amide}$

To a solution of 30 mgs. (0.049 mmol) of $5(S)\text{-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanoyl-Leucyl-Phenylalanyl Amide}$ in 10 mL of degassed dimethyl formamide (DMF) was added 10 mgs (0.074 mmol) of 1-hydroxybenzotriazole hydrate (HOBt), 14 mgs (0.074 mmol) of 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and 7 mgs (0.055 mmol) of thiophene-2-carboxylic acid. The pH of the solution was adjusted to ca. 9.0 with triethylamine and the reaction was stirred at room temperature. After 18 hours a TLC indicated that the coupling was complete. The DMF was removed in vacuo and the residue dissolved in 20 mL of methylene chloride which was washed with 2X20 mL of 10% citric acid soln., 20 mL of satd. NaHCO_3 solution and the organic layer was dried, filtered and concentrated to give the crude product. The residue was purified using prep. layer chromatography (50% MeOH/ CHCl_3 , SiO_2 , 0.5 mm plate) to give 18 mgs of the title compound m.p. 232-234°C.

EXAMPLE 2

Preparation of

$\text{N}'\text{-(3-phenylpropanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanoyl-Leucyl-Phenylalanyl amide, Compound E}$

To a solution of 0.038 mmol of $5(S)\text{-amino-4(S)-2(R)-(phenylmethyl)-hexanoyl-Leucyl-Phenylalanyl Amide}$ in 10 mL of methylene chloride which contained 10 μL (0.072 mmol) of triethylamine is added 10 μL (0.070 mmol) of 3-phenylpropanoyl chloride. After 3 hours the reaction is poured into a separatory funnel and washed with 2X10 mL of 10% citric acid solution, 10 mL of satd. NaHCO_3 solution. The organic phase is dried, filtered, and concentrated to dryness. The concentrate is passed through a pad of SiO_2 which is eluted with 50% MeOH/ CHCl_3 to give the crude product. This is further purified using reverse phase HPLC on a Water C-18 column to give the desired product.

EXAMPLE 3

Preparation of

$\text{N}'\text{-(1,1-Dimethylethylcarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(4-hydroxyphenylmethyl)hexanoyl-leucyl-phenylalanyl amide}$

Step A: Preparation of

$\text{N}'\text{-(1,1-Dimethylethoxycarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(4-hydroxyphenylmethyl)hexanoyl-leucyl-phenylalanyl amide}$

To a stirred solution of N'-(1,1-dimethylethoxycarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R) (4-benzoyloxyphenylmethyl)hexanoyl-leucyl-phenylalanyl amide, 25 mg, in 10 mL of tetrahydrofuran was added a suspension of 10% palladium on carbon, 25 mg, in 10 mL of abs. methanol. The mixture was stirred under an atmosphere of hydrogen for 4 hours at room temperature, then filtered and concentrated to dryness. The residue was dissolved in 1 mL of tetrahydrofuran and 1 mL of water was added. A white solid precipitated which was collected and dried under vacuum over P₂O₅. The yield was 20 mg of pure product mp 222-223 °C (C,H,N).

Step B: Preparation of

5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(4-hydroxyphenylmethyl)hexanoyl-leucyl-phenylalanyl amide

In a manner substantially similar to that described in Step K of Example 1, N'-(1,1-dimethylethoxycarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(4-hydroxyphenylmethyl)hexanoyl-leucyl-phenylalanyl amide is converted to the named product.

Step C: Preparation of

N'-(1,1-dimethylethoxycarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(4-hydroxyphenylmethyl)hexanoyl-leucyl-phenylalanyl amide

Following substantially the procedure described in Step L of Example 1, but employing the amine from Step B of this Example and pivalic acid, the described product is obtained.

EXAMPLE 4

Preparation of

N-benzyl-N'-(4-hydroxyphenylmethylcarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoic carboxamide

Step A: Preparation of

N-benzyl-N'-(1,1-dimethylethoxycarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoic carboxamide

The lithium salt of benzyl amine was prepared by adding 0.5 mL of a 2.5M solution of n-butyl lithium to 0.134 g of benzyl amine in 10 mL of dry THF at -78 °C. To this was added 0.1 g of (3R, 5S, 1'S)-3-benzyl-5-((1,1-dimethylethoxycarbonyl)amino)-2-phenylethyl)dihydrofuran-2-(3H)-one in 5 mL of THF. After stirring for 15 minutes, the reaction was quenched by the addition of 15 mL of 10% citric acid, and the mixture was allowed to warm to room temperature. The volume was tripled by the addition of ethyl acetate. The organic layer was separated, and the aqueous phase was washed with ethyl acetate. The combined organic solutions were washed with 3 x 10 mL 10% citric acid, 1 x 20 mL of saturated Na₂CO₃ solution, brine, and dried (Na₂SO₄). The solvent was removed in vacuo to yield a white solid. The solid was recrystallized from hexane/ethyl acetate to yield 0.065 g of the product as a crystalline solid; mp 191-192 °C.

Step B: Preparation of N-benzyl-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoic carboxamide

The amine protecting group is removed by following substantially the procedure described in Step K of Example 1 yielding desired product.

Step C: Preparation of

N-benzyl-N'-hydroxyphenylmethylcarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoic carboxamide

A new amine protecting group is added to the product of Step B of this Example, by following substantially the procedure described in Step L of Example 1, but replacing the 2-thiophenecarboxylic acid used therein, and substituting thereto 4-hydroxyphenylacetic acid. The indicated product is obtained.

EXAMPLE 5

Preparation of

N'-(1,1-dimethylethylaminosulfonyl)-4(S)-amino-3(S)-hydroxy-5-cyclohexylpentanoyl-leucyl-phenylalanyl amide

Step A: Preparation of

N-(1,1-dimethylethoxycarbonyl)-4(S)-amino-3(S)-hydroxy-5-cyclohexylpentanoyl-leucyl-phenylalanyl amide

N-(1,1-dimethylethoxycarbonyl)-4(S)-amino-3(S)-hydroxy-5-cyclohexylpentanoic acid (Boc-ACHPA) (0.575g, 1.82 mmol) was dissolved in 5.5 mL of dry DMF, under argon. To this well stirred mixture was added

L-leucyl-phenylalanine amide hydrochloride semihydrate (0.74g, 2.18 mmol), hydroxybenzotriazole hydrate (0.258g, 1.91 mmol), ethyl 3-dimethylamino)propylcarbodiimide hydrochloride (0.374g, 1.91 mmol), and triethylamine (0.57 mL, 4.10 mmol). This mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with ethyl acetate (30 mL). This mixture was washed with water (3X15 mL), 100% aqueous citric acid (15 mL), and brine (15 mL). Drying (Na_2SO_4), filtration, and removal of the solvent in vacuo gave the crude coupling product. This material was chromatographed on silica gel using 60% methanol in chloroform as eluant. There was obtained 0.582 g of the title compound as a white crystalline solid MP 171-175 °C.

Step B Preparation of 4(S)-amino-3(S)-hydroxy-5-cyclohexylpentanoyl-leucyl-phenylalanyl amide

The amine protecting group is removed by following substantially the procedure described in Step K of Example 1, yielding desired product.

Step C Preparation of

N'-[1,1-dimethylethylaminosulfonyl]-4(S)-amino-3(S)-hydroxy-5-cyclohexylpentanoyl-leucyl-phenylalanyl amide

A new amine protecting group is added to the product of Step B in this Example by following substantially the procedure described in Example 2, but replacing the 3-phenylpropanoyl chloride used therein and substituting thereto 1,1-dimethylethyl aminosulfonyl chloride. The indicated product is obtained.

EXAMPLE 6

Preparation of N'-[3-[(1(R)-Dimethylaminocarbonylamino-2-phenylethyl)phosphinyl]-2(R)-phenylmethyl propanoyl]-leucyl-phenylalanyl amide, and
N'-[3-[(1(R)-Benzyloxycarbonylamino-2-phenylethyl)phosphinyl]-2(S)-phenylmethyl propanoyl]-leucyl-phenylalanyl amide

Step A. Preparation of Methyl-1(R)-benzyloxycarbonylamino-2-phenylethylphosphinate

A 10% solution of trimethylsilyldiazomethane in pentane was added dropwise to a solution of 0.790 g of 1(R)-benzyloxycarbonylamino-2-phenylethyl phosphonous acid in a mixture of benzene (35 mL)/methanol (5 mL) until a pale yellow color persisted in the stirred reaction solution. After one hour at 0° the solution was concentrated and the residue chromatographed over silica gel, eluting with methylene chloride/acetone/methanol (18:1:1), to afford 0.400 g of pure methyl ester.

Step B Preparation of

Methyl-1(R)-benzyloxycarbonylamino-2-phenylethyl-(2(R,S)-carbomethoxy-3-phenyl-1-propyl)phosphinate

The product of Step A, 0.397g, was dissolved in 5 mL of abs. methanol and, at 0°, was treated with 0.67 mL of a 2.0 M solution of sodium methoxide in methanol under a nitrogen atmosphere. After 10 minutes, methyl 2-benzyl acrylate (0.240 g) was added in one portion, the cooling bath removed, and the mixture was stirred at ambient temperature of 18 hours. The mixture was concentrated to an oil which was partitioned between 15 mL of 1N hydrochloric acid and 10 mL of ethyl acetate. The layers were separated and the aqueous phase was extracted with 2X10 mL ethyl acetate. The combined organic layers were washed (brine) and dried (Na_2SO_4) and the solvent removed to give an oil which was chromatographed on silica gel (flash). Elution with ethyl acetate afforded 0.264 g of the product.

Step C. Preparation of

Methyl-1(R)-benzyloxycarbonylamino-2-phenylethyl-(2(R,S)-carbonyl-3-phenyl-1-propyl)phosphinate

A solution of the product of Step B, 0.264 g, in 1.5 mL of 1,2-dimethoxyethane was treated with 0.56 mL of a 1.0 N aqueous lithium hydroxide solution. After stirring under nitrogen for 4 hours at room temperature the solvent was removed and 30 mL ice water was added to the residue. The resulting mixture was extracted with 2X10 mL ether/ethyl acetate mixtures, following which the aqueous phase was acidified to pH 4-5 using several drops of 50% acetic acid. The acidic mixture was extracted with 3X15 mL ethyl acetate and then the combined acidic organic layers were washed with water, brine, and dried (MgSO_4). Removal of the solvent in vacuo left the product as an oil: 0.153 g.

Step D Preparation of

N-[3-[Methoxy-(1(R)-benzyloxycarbonylamino-2-phenylethyl)phosphinyl]-2-(R,S)-phenylmethyl-propanoyl]-leucyl-phenylalanyl amide

The product from Step C, 0.153 g, was dissolved in 4 mL of dry acetonitrile and stirred under nitrogen in an ice bath. To the solution were added 0.119 g of L-leucyl-L-phenylalanylamide hydrochloride hemihydrate, 0.155 g of benzotriazole-1-yl-oxytris(dimethylamino)phosphonium hexafluorophosphate, and triethylamine to pH 8.5. After stirring at 0° for 2 hours the mixture was warmed to room temperature and stirred 3 hours further. Ten mL of dilute aqueous sodium chloride was added and the mixture was extracted with 4X10 mL of ethyl acetate. The combined organic extracts were washed with water, 2N hydrochloric acid, water, saturated aqueous

sodium bicarbonate, brine, and dried MgSO_4). Removal of the solvent left 0.164 g of a sticky solid which was a mixture of 4 major components as evidenced by thin layer chromatography (chloroform/methanol/ammonium hydroxide, 90:10:1). The mixture was flash chromatographed, eluting with the same solvent mixture used for tlc. Early fractions containing an intimate mixture of 3 components were combined and concentrated to give 66 mg of a diastereomeric mixture of the product. Continued elution provided an additional 52 mg of product mixture which was predominately a single tlc spot.

Step E: Preparation of N-[3-[(1R)-Benzyloxycarbonylamino-2-phenylethyl]phosphinyl]-2(R)-phenylmethylpropanoyl]-leucyl-phenylalanyl amide, Compound Alpha, and N-[3-[(1R)-Benzyloxycarbonylamino-2-phenylethyl]phosphinyl]-2(S)-phenylmethylpropanoyl]-leucyl-phenylalanyl amide, Compound Beta

A solution containing 0.066 g of the diastereomeric mixture of Step D and 0.014 g of anhydrous lithium iodide in 2 mL dry tetrahydrofuran was stirred at room temperature for 7 days, during which time an additional 0.030 g of lithium iodide was added. At the end of 1 week the solvent was removed and the residue suspended in 5 mL of saturated sodium bicarbonate. The mixture was extracted with 4X5 mL ethyl acetate and the combined organic layers were concentrated. Separation of the two diastereomers was accomplished by preparative high pressure liquid chromatography using a Waters Delta Pak C-18 column, eluting with a gradient of acetonitrile 0-95% in water (0.1% trifluoroacetic acid) over one hour. The fractions of retention time 4.22 minutes and that of 7.00 minutes were lyophilized separately to afford 0.013 g of Compound Alpha and 0.012 g of Compound Beta, respectively.

Step F: Preparation of

N-[3-[(1R)-amino-2-phenylethyl]phosphinyl]-2(R)-phenylmethylpropanoyl]-leucyl-phenylalanyl amide

Following substantially the procedure described in Step A of Example 3, but substituting for the benzyl ether used therein, Compound Alpha from the preceding step, the indicated product is obtained.

Step G: Preparation of

N-[3-[(1R)-dimethylaminocarbonylamino-2-phenylethyl]phosphinyl]-2(R)-phenylmethylpropanoyl]-leucyl-phenylalanyl amide

Following substantially the procedure described in Example 2, but substituting for the amine used therein the product from the preceding step, and for the 3-phenylpropanoyl chloride used therein, dimethylaminocarbonyl chloride, the desired product is obtained.

EXAMPLE 7

Assay for Inhibition of Synthetic Viral Protease

Inhibition studies of the reaction of the synthetic protease [amino acid residues 69-167 of the pol open reading frame in Ratner, L. et al, *Nature*, 313, 277 (1985) and synthesized by Merrifield solid-phase synthesis] with a peptide substrate [Val-Ser-Gln-Asn-Tyr-Pro-Ile-Val, 2 mg/mL when the reaction is initiated] were in 50 mM Na acetate, pH 5.5, at 30°C for 1 hr. Various concentrations of inhibitor in 1.0 μL DMSO were added to 36 μL of assay solution and the reaction initiated by the addition of 4 μL (1.5 μg) of synthetic protease. The reaction was quenched with 160 μL of 12% acetic acid. Products of the reaction were separated by HPLC (VYDAC wide pore 5 cm C-18 reverse phase, acetonitrile gradient, 0.1% trifluoroacetic acid). The extent of inhibition of the reaction was determined from the peak heights of the products. HPLC of the products, independently synthesized, provided quantitation standards and confirmation of the product composition. Results are shown in Table VII.

TABLE VII

Compound	$\text{IC}_{50}(\text{nM})$
A	7
B	6
C	11
D	11
E	4

EXAMPLE 8

Preparation of N-benzyl-N'-(1,1-dimethylethoxycarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl isoleucyl amide, Compound F

Step A: Preparation of

N-benzyl-N'-(1,1-dimethylethoxycarbonyl)-5(S)-amino-4(S)-(1',1'-dimethylethyl-1,1-dimethylsiloxy)-6-phenyl-2(R)-(phenylmethyl)hexanoyl isoleucyl amide

The product of Example 1, Step H, 0.10 g (0.2 mmol) was dissolved in 2 ml of dry DMF, and to it was added 0.048 g (0.25 mmol) of EDC, 0.034 g (0.25 mmol) of HOBt and 0.077 g (0.3 mmol) of N-benzyl-isoleucyl amide hydrochloride. Triethylamine was added to the stirring solution until the pH was 8.5. After stirring for 18 hours, the reaction was poured into 20 ml of ice water and extracted with 3X20 ml of ethyl acetate. The combined organic extracts were washed with 1X20 ml of 10% citric acid, 1X20 ml of water, 1X20 ml of a saturated aqueous solution of Na_2CO_3 , 20 ml of brine dried (Na_2SO_4), and the solvent removed to give 0.125 g (86%) of Step A product after purification by chromatography on silica gel ($\text{CHCl}_3:\text{CH}_3\text{OH}$, 99:1).

Step B: Preparation of

N-benzyl-N'-(1,1-dimethylethoxycarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl) hexanoyl isoleucyl amide

The Step A product, 0.115 g, was placed in a flask and to it was added 2 ml of a 1M solution of tetrabutylammonium fluoride in THF. After stirring for 4 hours, the solvent was removed in vacuo, and the residue was treated with 20 ml of ice water to precipitate the white solid product. Chromatography on silica gel ($\text{CHCl}_3:\text{CH}_3\text{OH}$, 99:1) provided 0.035 g (36%) of Step B product. mp = 204-206°C;

elemental analysis calc'd. for $\text{C}_{37}\text{H}_{49}\text{N}_3\text{O}_8$:

	C, 72.17;	H, 8.02;	N, 6.82;
Found:	C, 72.47;	H, 8.30;	N, 6.73.

Step C: Preparation of N-benzyl

N'-(succinoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl isoleucyl amide

Removal of the Boc group and substituting thereto a succinoyl group was performed on the Step B product, 0.06 g (0.1 mmole), by the procedures of Example 9, both steps, to provide 0.03 g (49%) of the title compound. An analytical sample was obtained on recrystallization from acetonitrile;

elemental analysis calc'd for $\text{C}_{36}\text{H}_{46}\text{N}_3\text{O}_8$:

	C, 70.22;	H, 7.37;	N, 6.82;
Found:	C, 70.20;	H, 7.40;	N, 6.77.

EXAMPLE 9

Preparation of

N-(2(R)-hydroxy-1(S)-indanyl)-N'-(succinoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanoic carboxamide, Compound G

Step A: Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanoic carboxamide

A 0.25 g (0.46 mmol) quantity of N-(2(R)-hydroxy-1(S)-indanyl)-N'-(1,1-dimethylethoxycarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoic carboxamide was dissolved in 20 ml of dry CH_2Cl_2 with stirring and cooling in an ice water bath under argon. To this solution was added 5 ml of trifluoroacetic acid, and the solution was stirred for 2 hours. The reaction mixture was concentrated in vacuo, and the residue partitioned between CH_2Cl_2 and saturated aqueous sodium bicarbonate solution. The organic layer was separated, washed with brine and dried over anhydrous Na_2SO_4 , filtered and concentrated in vacuo to give 0.16 g (78%) of Step A product after chromatography on silica gel eluting with $\text{CHCl}_3:\text{CH}_3\text{OH}$, 95:5. An analytical sample was obtained by conversion to the maleate salt, mp 184-186°C;

elemental analysis, calc'd. for

$\text{C}_{28}\text{H}_{32}\text{N}_2\text{O}_7 \cdot \text{C}_4\text{H}_4\text{O}_4 \cdot \text{H}_2\text{O}$ (560.65):

	C, 66.41;	H, 6.62;	N, 4.84;
Found:	C, 66.50;	H, 6.35;	N, 4.78;

Step B: Preparation ofN-(2(R)-hydroxy-1(S)-indanyl)-N'-(succinoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanoic carboxamide

A 0.060 g (0.089 mmol) quantity of N-(2(R)-hydroxy-1(S)-indanyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanoic carboxamide was dissolved in 1 ml of dry DMF. To this solution was added 0.049 g (0.49 mmol) of succinic anhydride, and the reaction mixture was heated at 60°C for 8 hours. Ice water (20 ml) was added to the reaction mixture to precipitate 0.31 g (63%) of Step B product, mp 181-183°C after trituration with diethyl ether.

Elemental analysis, calc'd. for $C_{32}H_{36}N_2O_8$
(544.648):

	C, 70.57;	H, 6.66;	N, 5.14;
Found:	C, 70.84;	H, 6.81;	N, 5.12.

EXAMPLE 10Preparation ofN-(2(R)-hydroxy-1(S)-indanyl)-N'-(methanesulfonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanamide, Compound H.Step A: Preparation ofN-(2(R)-hydroxy-1(S)-indanyl)-5(S)-amino-4(S)-(1',1'-dimethyl-ethyl-1,1-dimethylsiloxy)-6-phenyl-2(R)-(phenylmethyl)-hexanamide

To a solution of 660 mgs. (0.99 mmol) of N-(2(R)-hydroxy-1(S)-indanyl)-5(S)-((1,1-dimethylethoxy)carbonyl)-amino-4(S)-(1',1'-dimethyl-ethyl-1,1-dimethylsiloxy)-6-phenyl-2(R)-(phenylmethyl)-hexanamide dissolved in 30 mls of methylene chloride at 0°C was added 15 mls of trifluoroacetic acid. After 30 minutes, a thin layer chromatogram (TLC) showed that the reaction was complete. The reaction solution was concentrated, the residue dissolved in 100 mls of methylene chloride and transferred to a separatory funnel. The organic layer was washed with 2X50 ml of satd. $NaHCO_3$ solution and the organic layer was dried (Na_2SO_4), filtered and concentrated to give the crude Step A product which was pure enough to be used in the next reaction.

Step B: Preparation ofN-(2(R)-hydroxy-1(S)-indanyl)-5(S)-(methanesulfonyl)amino-4(S)-1',1'-dimethyl-ethyl-1,1-dimethylsiloxy-6-phenyl-2(R)-(phenylmethyl)-hexanamide

To a solution of 55 mgs (0.10 mmol) of Step A product in 10 mls of methylene chloride was added 0.039 ml (0.276 mmol) of triethylamine and 0.032 mg (0.186 mmol) of methanesulfonic anhydride. The reaction was stirred at 23°C for 18 hours and worked up by diluting with 20 mls. of methylene chloride. The organic layer was washed with 2X20 mls of 10% citric acid soln., 20 mls of satd. $NaHCO_3$ solution, dried, filtered and concentrated to give the crude product. The residue was purified using prep. layer chromatography (10% MeOH/ $CHCl_3$, SiO_2 , 0.5 mm plate) to give 17 mgs of the Step B product compound as an oil.

Step C: Preparation ofN-(2(R)-hydroxy-1(S)-indanyl)-5(S)-(methanesulfonyl)amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanamide

To a solution of 50 mgs. (0.078 mmol) of Step B product in 2 mls of THF was added 1 ml of a 1M solution of tetrabutylammonium fluoride (TBAF). After 1 hour an additional 0.5 ml of TBAF was added. After 2 hours, the reaction was diluted with water and the resultant precipitate was filtered and washed with water. The solid was dissolved in chloroform, dried (Na_2SO_4), filtered and concentrated. The crude product was chromatographed on a prep. plate (0.5 mm, 5% MeOH/ $CHCl_3$) to give 24 mgs. of the Step C product, mp 180-182°C.

Anal. calc'd for $C_{28}H_{34}N_2O_5S \cdot 0.25 MeOH$:

	C, 66.20;	H, 6.65;	N, 5.28;
Found:	C, 65.96;	H, 6.59;	N, 5.65.

EXAMPLE 11

Preparation of

N-(2(R)-hydroxy-1(S)-indanyl)-N'-(5-o; o-2(S)-tetrahydrofuranylcarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanamide, Compound J

- 5 (S)-(+)-5-Oxo-2-tetrahydrofurancarboxylic acid, 0.020 g, was dissolved in 1 mL of dry DMF, and to it was added 0.007 g of 1-hydroxybenzotriazole hydrate, 0.010 g of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and 0.020 g of N-(2(R)-hydroxy-1(S)-indanyl-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanamide. Triethylamine was added to the stirring solution until the pH reached 8.5. After stirring for 12 hours at room temperature, the reaction was poured into 5 mL of water and extracted with 3X5 mL of ethyl acetate. The combined organic extracts were washed with 10% citric acid, water, saturated aqueous NaHCO_3 solution and dried over anhydrous Na_2SO_4 . Evaporation of the solvent gave a residue which was chromatographed over silica gel (5% methanol/chloroform) to afford the title compound as a white solid

EXAMPLE 12Assay for Inhibition of Microbial Expressed Viral Protease

- 15 Inhibition studies of the reaction of the protease expressed in *Escherichia coli* with a peptide substrate [Val-Ser-Gln-Asn-(betanaphthyl)Ala-Pro-Ile-Val, 0.5 mg/ml at the time the reaction is initiated] were in 50 mM Na acetate, pH 5.5, at 30° C for 1 hr. Various concentrations of inhibitor in 1.0 ul DMSO were added to 25 ul of the peptide solution in water. The reaction is initiated by the addition of 15 ul of 0.33 nM protease (0.11 ng) in a solution of 0.133 M Na acetate pH 5.5 and 0.267% bovine serum albumin. The reaction was quenched with 160 ul of 5% phosphoric acid. Products of the reaction were separated by HPLC (VYDAC wide pore 5 cm C-18 reverse phase, acetonitrile gradient, 0.1% phosphoric acid). The extent of inhibition of the reaction was determined from the peak heights of the products. HPLC of the products, independently synthesized, proved quantitation standards and configurations of the product composition. Compounds F, G, H and J showed IC_{50} values ranging from 0.5 to 10 nM.

- 20 While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations, modifications, deletions or additions of procedures and protocols described herein, as come within the scope of the following claims and its equivalents thereof.

35 Claims

1. Compounds of the formula:

A-G-B-B-J I,

wherein A is

40 1)

$\text{R}^1 - \overset{\text{O}}{\underset{\text{||}}{\text{C}}} -$ wherein R^1 is

a) C_{1-4} alkyl either unsubstituted or substituted with one or more of

i) C_{1-4} alkyl;

45 ii) hydroxy;

iii) carboxy;

iv) halo wherein halo is F, Cl, Br, or I; except no halo on carbon adjacent to carbonyl;

v) amino;

vi) C_{1-3} alkoxy carbonyl;

50 vii) C_{1-3} alkoxy;

viii) $-\text{CONR}^2\text{R}^3$ wherein R^2 and R^3 are the same or different and are hydrogen, C_{1-3} alkyl or C_{1-3} alkoxyalkyl or joined together either directly to form a 5-7 membered heterocycle, or through a heteroatom selected from N, O, and S, to form a 6-membered heterocycle with the nitrogen to which they are attached;


55 ix) $-\text{NR}^2\text{R}^3$;

x) $-\overset{\text{N}}{\underset{\text{||}}{\text{P}}} - \text{R}^4$ wherein,

R is hydrogen or C_{1-4} alkyl.

P is

60



65

and

R⁴ is H, C₁₋₃ alkyl, C₁₋₄ alkoxy, or NR²R³;

xi) C₃₋₇ cycloalkyl or C₆₋₁₀ aryl;

xii) 5 or 6 membered heterocycle, unsubstituted or substituted with OH, NH or C₁₋₄ alkyl, or

xiii) aryl of 6-10 carbon atoms, either unsubstituted or substituted with one or more of

(a) halo,

(b) hydroxy,

(c) C₁₋₃ alkoxy,

(d) C₁₋₃ alkyl,

(e) -NR₂, wherein R is defined above,

(f)




(g)



(h) -SO₂NR₂,

(i) -CH₂NR₂,

(j)



or

(k) -N(SO₂R):

(l)

xiv) -OSIR³(R²)₂

b) aryl of 6-10 carbon atoms, either unsubstituted or substituted with one or more of

i) C₁₋₄ alkyl,

ii) C₁₋₃ alkoxy,

iii) hydroxy, or

iv) halo;

v) -NR₂,

vi)




vii)



viii) -SO₂NR₂,

ix) -CH₂NR₂,

x)



or


xi) -N(SO₂R):

(l)

c) 5 or 6 membered heterocycle;

2) R¹-SO₂-, except R¹ is not aryl,


3)



wherein

R⁶ is H or C₁₋₃ alkyl or joined together with R¹ either directly to form 5-7 membered heterocycle, or through a heteroatom selected from N, O, and S, to form a 6-membered heterocycle with the nitrogen to which they are attached;


4)



5)

6) $\left[\begin{array}{c} \text{R}^{11} \\ | \\ \text{C} \\ | \\ \text{R}^{10} \end{array} \right]_n$ wherein q is 1 or 2;

G is

wherein Z is O, S, or HH, and R⁹ is independently

1) hydrogen;

2)

3) -OR, wherein R is H, or C₁₋₄ alkyl4) -NR₂,5) -C₁₋₄ alkylene-R¹¹;wherein n is 0-5 and R¹⁰ is independently

a) hydrogen,

b) hydroxy, or

c) C₁₋₄-alkyl;R¹¹ is

a) hydrogen,

b) aryl, unsubstituted or substituted with one or more of


i) halo,

ii) hydroxy,

iii) -NH₂, -NO₂, -NHR, or -NR₂, wherein R is H, or C₁₋₄ alkyl,iv) C₁₋₄ alkyl,v) C₁₋₃ alkoxy,

vi) -COOR,

vii)

viii) -CH₂NR₂,


ix)



x) CN,

xi) CF₃,

xii)

xiii) aryl C₁₋₃ alkoxy,

xiv) aryl,

xv) -NRSO₂R,xvi) -OP(O)(OR₁)₂ wherein R₁ is H or aryl, or

xvii)

$$\begin{array}{c} \text{O} \\ \parallel \\ -\text{O} - \text{C} - \text{C}_{1-4} \text{ alkyl substituted with one or more of amine or quaternary amine;} \end{array}$$

c) 5 or 6 membered heterocycle including up to 3 heteroatoms selected from N, O, and S, any of which heterocycle may be unsubstituted or substituted with one or more of

i) halo,

ii) hydroxy,

iii) $-NH_2$, $-NHR$, $-NR_2$,

iv) C_{1-4} alkyl,

v) C_{1-3} alkoxy,

vi) $-COOR$,

vii)

$\begin{array}{c} O \\ || \\ -C- \end{array}$

NR_2 ,

viii) $-CH_2NR_2$,

ix) $-NH \begin{array}{c} O \\ || \\ C- \end{array} R$,

x) $-CN$,

xi) CF_3 ,

xii) $-NHSO_2R$,

xiii) $-OP(O)(OR_x)_2$ wherein R_x is H or aryl, or

xiv)

$\begin{array}{c} O \\ || \\ -O- \end{array}$

C_{1-4} alkyl substituted with one or more of amine or quaternary amine;

d) C_{1-6} alkyl or C_{1-6} alkenyl, unsubstituted or substituted with one or more of

i) hydroxy,

ii) C_{1-4} alkyl,

iii) $-NH_2$, $-NHR$, $-NR_2$,

iv)

$-NH \begin{array}{c} NR \\ | \\ C- \end{array}$,

v)

$-NH \begin{array}{c} NR \\ | \\ C- \end{array} NH_2$,

vi) $-COOH$,

vii)

$\begin{array}{c} O \\ || \\ -C- \end{array}$

OR ,

viii) $-SR$ or arylthio,

ix) $-SO_2NHR$,

x) C_{1-4} alkyl sulfonyl amino or aryl sulfonyl amino,

xi) $-CONHR$,

xii)

$\begin{array}{c} O \\ || \\ -NH \end{array}$

$C- \end{array}$

xiii) $-OR$

xiv) aryl C_{1-3} alkoxy, or,

xv) aryl;

e) C_{3-7} cycloalkyl unsubstituted or substituted with one or more of

i) hydroxy,

ii) C_{1-4} alkyl,

iii) $-NH_2$, $-NHR$, $-NHR_2$,

iv)

$-NH \begin{array}{c} NR \\ | \\ C- \end{array}$,

v)

$-NH \begin{array}{c} NR \\ | \\ C- \end{array} NH_2$,

vi) $-COOH$,

vii)

$\begin{array}{c} O \\ || \\ -C- \end{array}$

OR ,

viii) $-SR$,

ix) $-SO_2NH_2$,

x) alkyl sulfonylamin or aryl sulfonylamin,

xi) $-CONHR$, or

xii)



f) a 5- to 7-membered carbocyclic or 7- to 10-membered bicyclic carbocyclic ring which is either saturated or unsaturated, said carbocyclic ring being unsubstituted or substituted with one or more of

i) halo

ii) -OR, wherein R is H or C₁₋₄ alkyl.

iii)



iv)



v) -CH₂NR₂.

vi) -SO₂NR₂ or -S(O)_yR, R wherein y is 0, 1, or 2;

vii) -NR₂.

viii)



ix) C₁₋₄ alkyl.

x) phenyl.

xi) -CF₃, or

xii)



g) benzofuryl; indolyl; azabicyclo C₇₋₁₁ cycloalkyl; or benzopiperidiny;

R¹² is -OH or -NHR¹³, wherein R¹³ is -H.



-R¹¹-C₁₋₄-alkyl or -COOR; and

(H) is

1) C₆₋₇ cycloalkyl either unsubstituted or substituted with one or more of

a) C₁₋₄ alkyl.

b) hydroxy.


c) -NR₂.

d) -COOR.

e) CONHR.

f) -NHSO₂R.

g)



h) aryl.

i) aryl substituted with C₁₋₄ alkyl.

j) heterocycle, or

k) heterocycle substituted with C₁₋₄ alkyl;

2) phenyl, either unsubstituted or substituted with one or more of

a) hydroxy.

b) -OR.

c) -NHR¹³.

d) -COOR.

e)



f)



3) 5 to 7-membered heterocycle, any of which heterocycle may be unsubstituted or substituted with one or more of

i) halo,


ii) hydroxy.

iii) NR₂, or

iv) C₁₋₄ alkyl;

Q is






wherein R^9 and R^{13} are defined above; X is O, S, or NH; and

W is

- 1) OH,
- 2) NH_2 ,
- 3) OR, or
- 4) NHR;

B is, independently, absent, or




J is

- 1) YR^{14} wherein:


Y is O or NH, and

R^{14} is


- a) H;
- b) C_{1-4} alkyl, unsubstituted or substituted with one or more of
 - i) ---NR_2^7 ,
 - ii) ---OR ,
 - iii) $\text{---NHSO}_2\text{C}_{1-4}$ alkyl,
 - iv) ---NHSO_2 aryl, or ---NHSO_2 (dialkylaminoaryl),
 - v) $\text{---CH}_2\text{OR}$,
 - vi) ---C_{1-4} alkyl,
 - vii) ---C(=O)OR ,
 - viii) ---NR_2 ,
 - ix) ---NR_2 .



x)



xii)



xiii) $\text{---NR}_3^+ \text{A}^-$ wherein A^- is a counterion,

xiv) $\text{---NR}^{15}\text{R}^{16}$ wherein R^{15} and R^{16} are the same or different and are C_{1-5} alkyl joined together directly to form a 5-7 membered heterocycle,

xv) aryl,


xvi) ---CHO ,

xvii) $\text{---OP(O)(OR}_2)_2$ wherein R_2 is H or aryl, or

xviii)

$\text{---O---C(=O)---C}_{1-4}$ alkyl substituted with one or more of amine or quaternary amine;

- c) $-(\text{CH}_2\text{CH}_2\text{O})\text{CH}_3$ or $-(\text{CH}_2\text{CH}_2\text{O})_n\text{H}$;
 2) $-\text{N}(\text{R}^{14})_2$;
 3) $-\text{NR}^{15}\text{R}^{16}$ wherein R^{15} and R^{16} are defined above;
 4)



wherein:

Y, R^{14} , and n are defined above, and R^{17} is

a) hydrogen;

b) aryl unsubstituted or substituted with one or more of

i) halo,

ii) $-\text{OR}$, wherein R is H or C_{1-4} alkyl,

iii)



iv)



v) $-\text{CH}_2\text{NR}_2$,

vi) $-\text{SO}_2\text{NR}_2$,

vii) $-\text{NR}_2$,

viii)



ix) C_{1-4} alkyl,

x) phenyl,

xi) $-\text{CF}_3$,


xii)



xiii) $-\text{C}_{1-4}$ alkyl- NR_2 ,

xiv) $-\text{OP}(\text{O})(\text{OR}_2)_2$ wherein R_2 is H or aryl, or

xv)



c) heterocycle, unsubstituted or substituted with one or more of

i) halo,

ii) $-\text{OR}$, wherein R is H, C_{1-4} alkyl, or C_{1-4} alkenyl,

iii)



iv)



v) $-\text{CH}_2\text{NR}_2$,

vi) $-\text{SO}_2\text{NR}_2$,

vii) $-\text{NR}_2$,

viii)



ix) C_{1-4} alkyl,

x) phenyl,

xi) $-\text{CF}_3$,

xii)



xiii) phenyl C_{1-4} alkyl.

xiv)

xv) $-\text{OP}(\text{O})(\text{OR}_1)_2$ wherein R_1 is H or aryl, or

xvi)



d) A 5- to 7-membered carbocyclic or 7- to 10-membered bicyclic carbocyclic ring which is either saturated or unsaturated, the carbocyclic ring being unsubstituted or substituted with one or more of

i) halo,

ii) $-\text{OR}$, wherein R is H or C_{1-4} alkyl,

iii)



iv)

v) $-\text{CH}_2\text{NR}_2$,vi) $-\text{SO}_2\text{NR}_2$,vii) $-\text{NR}_2$,

viii)

ix) C_{1-4} alkyl,

x) phenyl,

xi) $-\text{CF}_3$,

xii)




xiii) $-\text{OP}(\text{O})(\text{OR}_1)_2$ wherein R_1 is H or aryl, or

xiv)




or pharmaceutically acceptable salts thereof.

2. The compounds of Claim 1 wherein B is independently present twice and Z is O.


3. The compounds of Claim 2 wherein J is NH_2 , and Q is4. The compounds of Claim 2 wherein J is NH_2 , and Q is5. The compounds of Claim 2 wherein J is NH_2 , and Q is

6. The compounds of Claim 1 wherein B is present once and Z is O.


7. The compounds of Claim 6 wherein Q is




10 8. The compounds of Claim 6 wherein Q is



20 9. The compounds of Claim 6 wherein Q is




30 10. The compounds of Claim 1 wherein B is always absent.
11. The compounds of Claim 10 wherein Q is




40 12. The compounds of Claim 10 wherein Q is




50 13. The compounds of Claim 10 wherein Q is



60 14. The compounds of Claim 1 wherein G is:




15. Compounds of Claim 1 wherein G is:




and B is absent or present once.

16. Compounds of Claim 1 wherein G is




B is absent or present once; and




17. Compounds of Claim 1 wherein:

A is

$\text{R}^1 - \overset{\text{O}}{\parallel} \text{C} -$ or $\text{R}^1 - \text{SO}_2 -$, with the proviso that R^1 is not aryl when attached to S;
G is:



B is absent or present once; and



18. N'-(1,1-dimethylethylaminocarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-leucyl-phenylalanylamide, or pharmaceutically acceptable salt thereof.

19. N'-(2,2-dimethylpropanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-leucyl-phenylalanylamide, or pharmaceutically acceptable salt thereof.

20. N'-(2-thienoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-leucyl-phenylalanylamide, or pharmaceutically acceptable salt thereof.

21. N'-(3,3-dimethylbutanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-leucyl-phenylalanylamide, or pharmaceutically acceptable salt thereof.

22. N'-(3-phenylpropanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-leucyl-phenylalanylamide, or pharmaceutically acceptable salt thereof.

23. N-benzyl-N'-(succinoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl isoleucyl amide;

N-(2(R)-hydroxy-1(S)-indanyl)-N'-(succinoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanamide;

N-(2(R)-hydroxy-1(S)-indanyl)-N'-(methanesulfonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanamide;

N-(2(R)-hydroxy-1(S)-indanyl)-N'-(5-oxo-2(S)-tetrahydrofuran-2-carbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanamide.

N'-(2,2-dimethylpropanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl) hexanoyl-Leu, Phe-
amide.

N'-(1,1-dimethylethylaminocarbonyl)-5(S)-amino-4(S)-hydroxy-2(R)-phenylmethyl-hexanoyl-Leucyl-Phe-
nylalanyl-amide.

5 N'-(3-phenylpropanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanoyl-Leucyl-Phe-
nylalanyl-amide.

N'-(Succinoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-N-(phenylmethyl)-Ile-
amide.

10 N-(2(R)-hydroxy-1(S)-indanyl)-N'-(4-[1-butyl-dimethylsilyloxy]butanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-
2(R)-(phenylmethyl)hexanamide.

N-(2(R)-hydroxy-1(S)-indanyl)-N'-(methanesulfonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylme-
thyl)hexanamide.

N-(2(R)-hydroxy-1(S)-indanyl)-N'-(4-hydroxybutanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-phe-
nylmethyl hexanamide.

15 N'-(methanesulfonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-N-[2,3-dihydroxy-
propyl]-Val-amide, or

N-(2(R)-hydroxy-1(S)-indanyl)-N'-[2-(2-methoxyethoxy)ethoxy]ethoxycarbonyl-5(S)-amino-
2(R)-benzyl-4(S)-hydroxy-6-phenyl hexanamide.

or pharmaceutically acceptable salts thereof.

20 24. The compounds of Claims 1-23, in combination with any of the antivirals, immunomodulators,
antibiotics or vaccines of Table VI.

25 25. A pharmaceutical composition comprising the compounds of Claims 1-23, and a pharmaceutically
acceptable carrier.

26. A pharmaceutical composition comprising the compound in combination according to Claim 24, and
a pharmaceutically acceptable carrier.

27. The pharmaceutical composition of Claim 25, for use in the treatment of AIDS, in the prevention of
infection by HIV, in the treatment of infection by HIV, or in the inhibition of HIV protease.

28. The pharmaceutical composition of Claim 26, for use in the treatment of AIDS, in the prevention of
infection by HIV, in the treatment of infection by HIV, or in the inhibition of HIV protease.

30 29. The use of a compound of any one of Claims 1-23, for the preparation of a medicament useful for
treating AIDS.

30. The use of a combination according to Claim 24, for the preparation of a medicament useful for
treating AIDS.

31. The use of a compound as claimed in any one of Claims 1-23, for the preparation of a medicament
useful for preventing infection by HIV.

32. The use of the combination as claimed in Claim 24 for the preparation of a medicament useful for
preventing infection by HIV.

33. The use of a compound as claimed in any one of claims 1-23 for the preparation of a medicament
useful for treating infection by HIV.

40 34. The use of the combination as claimed in Claim 24 for the preparation of a medicament useful for
treating infection by HIV.

35. The use of a compound as claimed in any one of claims 1-23 for the preparation of a medicament
useful for inhibiting HIV protease.

45 36. The use of the combination as claimed in Claim 24 for the preparation of a medicament useful for
inhibiting HIV protease.

Claims for the following Contracting States: ES, GR

1.- A process for preparing HIV protease inhibitors, useful for the treatment of AIDS, having formula I

50 A-G-B-B-J I,

wherein A is

1)



wherein R¹ is

55 a) C₁₋₆ alkyl either unsubstituted or substituted with one or more of

i) C₁₋₄ alkyl;

ii) hydroxy;

iii) carboxy;

iv) halo wherein halo is F, Cl, Br, or I; except no halo on carbon adjacent to carbonyl;

60 v) amino;

vi) C₁₋₃ alkoxy carbonyl;

vii) C₁₋₃ alkoxy;

65 viii) -CONR²R³ wherein R² and R³ are the same or different and are hydrogen, C₁₋₃ alkyl or C₁₋₃
alkoxyalkyl or joined together either directly to form a 5-7 membered heterocycle, or through a
heteroatom selected from N, O, and S, to form a 6-membered heterocycle with the nitrogen to which they


are attached;

ix) $-NR^2R^3$;

x) $-N-P-R^4$ wherein,

R is hydrogen or C₁₋₄ alkyl,

P is



and

R⁴ is H, C₁₋₃ alkyl, C₁₋₄ alkoxy, or NR²R³;

xii) C₃₋₇ cycloalkyl or C₆₋₁₀ aryl;

xiii) 5 or 6 membered heterocycle, unsubstituted or substituted with OH, NH or C₁₋₄ alkyl, or

xiii) aryl of 6-10 carbon atoms, either unsubstituted or substituted with one or more of

(a) halo,

(b) hydroxy,

(c) C₁₋₃ alkoxy,

(d) C₁₋₃ alkyl,

(e) $-NR_2$, wherein R is defined above,

(f)




(g)



(h) $-\text{SO}_2\text{NR}_2$,

(i) $-\text{CH}_2\text{NR}_2$,

(j)



or

(k) $-N \text{ SO}_2\text{R}$;

xiv) $-\text{OSiR}^3(\text{R}^2)_2$

b) aryl of 6-10 carbon atoms, either unsubstituted or substituted with one or more of

i) C₁₋₄ alkyl,

ii) C₁₋₃ alkoxy,

iii) hydroxy, or

iv) halo;

v) $-NR_2$,

vi)




vii)



viii) $-\text{SO}_2\text{NR}_2$,

ix) $-\text{CH}_2\text{NR}_2$,

x)




or

xi) $-N \text{ SO}_2\text{R}$;

R


- c) 5 or 6 membered heterocycle;
 2) R^1-SO_2- , except R^1 is not aryl
 3)




wherein

- R^5 is H or C_{1-4} alkyl or joined together with R^1 either directly to form 5-7 membered heterocycle, or through a heteroatom selected from N, O, and S, to form a 6-membered heterocycle with the nitrogen to which they are attached;


4)



5)




- 6) $(R^1)_q$ wherein q is 1 or 2;
 G is



wherein Z is O, S, or HH, and
 R^9 is independently

- 1) hydrogen;
 2)



3) $-OR$, wherein R is H, or C_{1-4} alkyl

4) $-NR_2$.

- 5) $-C_{1-4}$ alkylene- R^{11} ;
 wherein n is 0-5 and R^{10} is independently

- a) hydrogen,
 b) hydroxy, or
 c) C_{1-4} alkyl;

R^{11} is

- a) hydrogen,
 b) aryl, unsubstituted or substituted with one or more of
 i) halo,

ii) hydroxy,


- iii) $-NH_2$, $-NO_2$, $-NHR$, or $-NR^2$, wherein R is H, or C_{1-4} alkyl,

iv) C_{1-4} alkyl,

v) C_{1-3} alkoxy,


vi) $-COOR$,

vii)



viii) $-CH_2NR_2$.

ix)



- x) CN,
 xi) CF₃,
 xii)

$$\begin{array}{c} \text{O} \\ \parallel \\ \text{-NH-C-R}_1 \end{array}$$

 xiii) aryl C₁₋₃ alkoxy,
 xiv) aryl,
 xv) -NRSO₂R,
 xvi) -OP(O)(OR₁)₂ wherein R₁ is H or aryl, or
 xvii)
- $$\begin{array}{c} \text{O} \\ \parallel \\ \text{-O-C-C}_{1-4} \text{ alkyl substituted with one or more of amine or quaternary amine.} \end{array}$$

 c) 5 or 6 membered heterocycle including up to 3 heteroatoms selected from N, O, and S, any of which heterocycle may be unsubstituted or substituted with one or more of
- i) halo,
 ii) hydroxy,
 iii) -NH₂, -NHR, -NR₂,
 iv) C₁₋₄ alkyl,
 v) C₁₋₃ alkoxy,
 vi) -COOR,
 vii)

$$\begin{array}{c} \text{O} \\ \parallel \\ \text{-C-NR}_2 \end{array}$$

 viii) -CH₂NR₂,
 ix) -NH-C-R₁
- $$\begin{array}{c} \text{O} \\ \parallel \\ \text{-NH-C-R}_1 \end{array}$$

 x) -CN,
 xi) CF₃,
 xii) -NHSO₂R,
 xiii) -OP(O)(OR₁)₂ wherein R₁ is H or aryl, or
 xiv)
- $$\begin{array}{c} \text{O} \\ \parallel \\ \text{-O-C-C}_{1-4} \text{ alkyl substituted with one or more of amine or quaternary amine;} \end{array}$$

 d) C₁₋₈ alkyl or C₁₋₈ alkenyl, unsubstituted or substituted with one or more of
- i) hydroxy,
 ii) C₁₋₄ alkyl,
 iii) -NH₂, -NHR, -NR₂,
 iv)
- $$\begin{array}{c} \text{NR}_2 \\ \parallel \\ \text{-NH-C-R}_1 \end{array}$$

 v)
- $$\begin{array}{c} \text{NR}_2 \\ \parallel \\ \text{-NH-C-NH}_2 \end{array}$$

 vi) -COOH,
 vii)

$$\begin{array}{c} \text{O} \\ \parallel \\ \text{-C-OR}_1 \end{array}$$

 viii) -SR or arylthio,
 ix) -SO₂NHR,
 x) C₁₋₄ alkyl sulfonyl amino or aryl sulfonyl amino,
 xi) -CONHR,
 xii)
- $$\begin{array}{c} \text{O} \\ \parallel \\ \text{-NH-C-R}_1 \end{array}$$


 xiii) -OR
 xiv) aryl C₁₋₃ alkoxy, or,
 xv) aryl;
- e) C₃₋₇ cycloalkyl unsubstituted or substituted with one or more of
- i) hydroxy,
 ii) C₁₋₄ alkyl,
 iii) -NH₂, -NHR, -NR₂,
 iv)
- $$\begin{array}{c} \text{NR}_2 \\ \parallel \\ \text{-NH-C-R}_1 \end{array}$$

 v)

- $\text{-NH-}\overset{\text{NE}}{\underset{\text{O}}{\parallel}}\text{C- NH}_2$
 vi) -COOH ,
 vii) $\overset{\text{O}}{\parallel}\text{C-OR}$,
 5 viii) -SR ,
 ix) $\text{-SO}_2\text{NH}_2$,
 x) alkyl sulfonylamino or aryl sulfonylamino,
 10 xi) -CONHR , or
 xii) $\overset{\text{O}}{\parallel}\text{C R}$;
 f) a 5- to 7-membered carbocyclic or 7- to 10-membered bicyclic carbocyclic ring which is either saturated
 15 or unsaturated, said carbocyclic ring being unsubstituted or substituted with one or more of
 i) halo
 ii) -OR , wherein R is H or C_{1-4} alkyl,
 iii) $\overset{\text{O}}{\parallel}\text{C OR}$,
 20 iv) $\overset{\text{O}}{\parallel}\text{C NR}_2$,
 v) $\text{-CH}_2\text{NR}_2$,
 25 vi) $\text{-SO}_2\text{NR}_2$ or $\text{-S(O)}_y\text{R}$ wherein y is 0, 1, or 2;
 vii) -NR_2 ,
 viii) $\overset{\text{O}}{\parallel}\text{C R}$,
 30 ix) C_{1-4} alkyl,
 x) phenyl,
 xi) -CF_3 , or
 xii) $\overset{\text{X}}{\parallel}\text{N-SO}_2\text{R}$;
 35 g) benzofuryl; indolyl; azabicyclo C₇₋₁₁ cycloalkyl; or benzopiperidinyI;
 R^{12} is -OH or -NHR^{13} , wherein R^{13} is -H ,
 $\overset{\text{O}}{\parallel}\text{C H}$, $\text{-C}_{1-4}\text{-alkyl}$ or -COOR ; and
 40 (H) is
 1) C_{3-7} cycloalkyl either unsubstituted or substituted with one or more of
 a) C_{1-4} alkyl,
 b) hydroxy,
 c) -NR_2 ,
 45 d) -COOR ,
 e) CONHR ,
 f) $\text{-NHSO}_2\text{R}$,
 g) $\overset{\text{O}}{\parallel}\text{C R}$,
 50 h) aryl,
 i) aryl substituted with C_{1-4} alkyl,
 j) heterocycle, or
 k) heterocycle substituted with C_{1-4} alkyl;
 55 2) phenyl, either unsubstituted or substituted with one or more of
 a) hydroxy,
 b) -OR ,
 c) -NHR^{13} ,
 d) -COOR ,
 60 e) $\overset{\text{O}}{\parallel}\text{C NR}_2$, or
 f) $\overset{\text{O}}{\parallel}\text{C R}$; or
 65 $\text{-NH}\overset{\text{O}}{\parallel}\text{C R}$; or

3) 5 to 7-membered heterocycle, any of which heterocycle may be unsubstituted or substituted with one or more of

- i) halo,
 - ii) hydroxy,
 - iii) NR_2 , or
 - iv) C_{1-4} alkyl;
- Q is




wherein R^9 and R^{13} are defined above; X is O, S, or NH; and

W is

- 1) OH,
- 2) NH_2 ,
- 3) OR, or
- 4) NHR;

B is, independently, absent, or



J is

1) YR^{14} wherein:

Y is O or NH, and

R^{14} is

a) H;

b) C_{1-4} alkyl, unsubstituted or substituted with one or more of

i) $-\text{NR}_2$,

ii) $-\text{OR}$,

iii) $-\text{NHSO}_2\text{C}_{1-4}$ alkyl,

iv) $-\text{NHSO}_2$ aryl, or $-\text{NHSO}_2$ (dialkylaminoaryl),

v) $-\text{CH}_2\text{OR}$,

vi) $-\text{C}_{1-4}$ alkyl,


vii)



viii)




ix)




x)



xi)



xii)



xiii) $-NR_3^+A^-$ wherein A^- is a counterion.

xiv) $-NR^{15}R^{16}$ wherein R^{15} and R^{16} are the same or different and are C_{1-6} alkyl joined together directly to form a 5-7 membered heterocycle.

xv) aryl.

xvi) $-CHO$.

xvii) $-OP(O)(OR_1)_2$ wherein R_1 is H or aryl, or

xviii)


$-O-\overset{\overset{O}{\parallel}}{C}-C_{1-4}$ alkyl substituted with one or more of amine or quaternary amine.

c) $-(CH_2CH_2O)CH_3$ or $-(CH_2CH_2O)_nH$;

2) $-N(R^{14})_2$;

3) $-NR^{15}R^{16}$ wherein R^{15} and R^{16} are defined above;

4)



wherein:

Y, R^{14} , and n are defined above, and

R^{17} is

a) hydrogen;

b) aryl unsubstituted or substituted with one or more of

i) halo,

ii) $-OR$, wherein R is H or C_{1-4} alkyl,

iii)

$-\overset{\overset{O}{\parallel}}{C}OR$,

iv)

$-\overset{\overset{O}{\parallel}}{C}NR_2$,

v) $-CH_2NR_2$,

vi) $-SO_2NR_2$,

vii) $-NR_2$,

viii)

$-\overset{\overset{O}{\parallel}}{NH}C-R$,

ix) C_{1-4} alkyl,

x) phenyl,

xi) $-CF_3$,

xii)

$-\overset{\overset{O}{\parallel}}{N}-SO_2R$,

xiii) $-C_{1-4}$ alkyl- NR_2 ,

xiv) $-OP(O)(OR_1)_2$ wherein R_1 is H or aryl, or

xv)

$-O-\overset{\overset{O}{\parallel}}{C}-C_{1-4}$ alkyl substituted with one or more of amine or quaternary amine;

c) heterocycle, unsubstituted or substituted with one or more of

i) halo,

ii) $-OR$, wherein R is H, C_{1-4} alkyl, or C_{1-4} alkenyl.

iii)

$-\overset{\overset{O}{\parallel}}{C}OR$,

iv)

$-\overset{\overset{O}{\parallel}}{C}NR_2$,

v) $-CH_2NR_2$,

vi) $-SO_2NR_2$,

vii) $-NR_2$,

viii)

ix) C₁₋₄ alkyl.

x) phenyl.

xi) -CF₃.

xii)

-N-SO₂R.xiii) phenyl C₁₋₄ alkyl.

xiv)



-O-C-R.

xv) -OP(O)(OR₁)₂ wherein R₁ is H or aryl, or

xvi)



d) A 5- to 7-membered carbocyclic or 7- to 10-membered bicyclic carbocyclic ring which is either

saturated or unsaturated, the carbocyclic ring being unsubstituted or substituted with one or more of

i) halo.

ii) -OR, wherein R is H or C₁₋₄ alkyl.

iii)



-C-OR.

iv)

-C-NR₂.v) -CH₂NR₂.vi) -SO₂NR₂.vii) -NR₂.

viii)



-NH-C-R.

ix) C₁₋₄ alkyl.

x) phenyl.

xi) -CF₃.

xii)

-N-SO₂R.xiii) -OP(O)(OR₁)₂ wherein R₁ is H or aryl, or

xiv)



or pharmaceutically acceptable salts thereof,

said process being characterized by


a) forming the desired G component duly protected on its amine group;

b) coupling on to the carboxy terminal end of said protected G component the other components B (if present) and/or J, either one by one or together, each component being duly protected when necessary by protecting groups which are adequate to both the particular coupling conditions and the amino acid components and analogs thereof involved in the synthesis, by forming amide bonds by any coupling method of either solution-phase or solid-phase peptide synthesis;


c) removing the amine protecting group originally contained in the G component and adding the amine protecting group not useful or commonly employed in peptide synthesis (A) by reaction of the amine obtained with the desired A-derivative; and

d) removing any additional protecting group which could be present if desired, or if necessary.


2. The process of Claim 1 wherein B is independently present twice and Z is O.

3. The process of Claim 2 wherein J is NH₂, and Q is


4. The process of Claim 2 wherein J is NH_2 , and Q is



10 5. The process of Claim 2 wherein J is NH_2 , and Q is




20 6. The process of Claim 1 wherein B is present once and Z is O.
7. The process of Claim 6 wherein Q is




30 8. The process of Claim 6 wherein Q is




40 9. The process of Claim 6 wherein Q is




50 10. The process of Claim 1 wherein B is always absent.
11. The process of Claim 10 wherein Q is




60 12. The process of Claim 10 wherein Q is




13. The process of Claim 10 wherein Q is



14. The process of Claim 1 wherein G is:




15. The process of Claim 1 wherein G is:




and B is absent or present once.

16. The process of Claim 1 wherein G is




B is absent or present once; and




17. The process of Claim 1 wherein:

A is

$\text{R}^1-\overset{\text{O}}{\underset{\text{O}}{\text{C}}}-$ or R^1-SO_2- , with the proviso that R^1 is not aryl when attached to S;
G is:



B is absent or present once; and



18. The process of claim 1, wherein the compound obtained is N'-(1,1-dimethylethylaminocarbonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-leucyl-phenylalanyl-amide, or pharmaceutically acceptable salt thereof.

19. The process of claim 1, wherein the compound obtained is N'-(2,2-dimethylpropanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-leucyl-phenylalanyl-amide, or pharmaceutically acceptable salt thereof.

20. The process of claim 1, wherein the compound obtained is N'-(2-thienoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-leucyl-phenylalanyl-amide, or pharmaceutically acceptable salt thereof.

21. The process of claim 1, wherein the compound obtained is N'-(3,3-dimethylbutanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-leucyl-phenylalanyl-amide, or pharmaceutically acceptable salt thereof.

22. The process of claim 1, wherein the compound obtained is N'-(3-phenylpropanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-leucyl-phenylalanyl-amide, or pharmaceutically acceptable salt thereof.

23. The process of claim 1, wherein the compound obtained is selected from N-benzyl-N'-(succinoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-isoleucyl-amide;

N-(2(R)-hydroxy-1(S)-indanyl)-N'-(succinoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanamide;

N-(2(R)-hydroxy-1(S)-indanyl)-N'-(methanesulfonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanamide;

N-(2(R)-hydroxy-1(S)-indanyl)-N'-(5-oxo-2(S)-tetrahydrofurancarboxyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanamide.

N'-(2,2-dimethylpropanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-Leu-Phe-amide,

N'-(1,1-dimethylethylaminocarbonyl)-5(S)-amino-4(S)-hydroxy-2(R)-phenylmethyl-hexanoyl-Leucyl-Phe-nylalanyl-amide,

N'-(3-phenylpropanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)-hexanoyl-Leucyl-Phe-nylalanyl-amide,

N'-(Succinoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-N-(phenylmethyl)-Ile-amide,

N-(2(R)-hydroxy-1(S)-indanyl)-N'-(4-(4-butylidimethylsilyloxybutanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanamide,

N-(2(R)-hydroxy-1(S)-indanyl)-N'-(methanesulfonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanamide,

N-(2(R)-hydroxy-1(S)-indanyl)-N'-(4-hydroxybutanoyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-phe-nylmethyl hexanamide,

N'-(methanesulfonyl)-5(S)-amino-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl-N-[2,3-dihydroxy-propyl]-Val-amide, or

N-(2(R)-hydroxy-1(S)-indanyl)-N'-[2-(2-methoxyethoxy)ethoxy]ethoxycarbonyl]-5(S)-amino-2(R)-benzyl-4(S)-hydroxy-6-phenyl hexanamide,

or pharmaceutically acceptable salts thereof.